Biologist Carl Bergstrom on coronavirus, misinformation and why we weren’t prepared – CNBC

Carl Bergstrom is an infectious disease expert who's been thinking about the relationship between biology and social systems. One central theme in his work is information: How it flows and how it spreads.

At the University of Washington, where he lectures, he developed an online course called "calling bull----" to help students use critical reasoning to see through false health information.Off the back of the syllabus' popularity, Bergstrom and his colleague Jevin West wrote a book filledwithadviceabouthow mainstream audiences can use statistics and other data science tools to question hyped-up products and conspiracy theories that are pervasive on our social media feeds today.

There are a lot of information gaps when it comes to the COVID-19 virus. And Bergstrom is one of the scientists desperately trying to fill those gaps.

He says that early on, some of the information coming out of China felt like misinformation because it was coming from political opponents of the Chinese government, but it turned out to be "partially right." Since then, he's been noting and occasionally debunking various conspiracy theories and rumors, such as the idea that the coronavirus was a Chinese bioweapon -- and, in China, that it's a U.S. bioweapon -- and false stories of catastrophes at American hospitals. On Twitter, he also called out a neurologist, Scott Mintzer, for a "panic inducing" thread about a health system in Seattle, which was based on a second-hand account from an unnamed doctor.

Bergstrom also says that there's been plenty of anticipation of a respiratory viral pandemic like COVID-19, but he does not blame the slow response in the U.S. entirely on the current government. Rather, he notes it's politically challenging to fund pandemic preparedness without a clear and present threat.

"There was a denial and refusal to act that lost us some time, and that's part of what happened. But we also didn't have the resources in place to respond to a pandemic in terms of our coordination structure," Bergstrom said. "There's a 'not on my watchism,' which involves a choice between doing a politically unpopular thing to provide funding for pandemic preparedness that might not come, or avoid doing that and slash whatever is there. These are perceived as once-in-a-century catastrophes."

He argues that the government must play a central role in planning and responding to such catastrophes, and that advocates of small-government philosophy should understand this kind of planning is akin to raising a military.

"There are some collective action problems that even the Chicago-school economists acknowledge will not be adequately solved by the market," he says. "No one expects us to raise a powerful standing army based on private market forces (and) we consider that a central role of the government to provide national defense. Pandemic preparedness is the same."

He also suggests that current lockdowns may need to last past the summer in some areas, unless we can increase testing capacity.

"My personal feeling is that we either have a long lockdown ahead of us, or we'll get testing capacity way up."

Here's a transcript of the interview, edited for length and clarity:

FARR: Given that you track how information spreads, both true and false, where and when did you see the first groups really start to sound the alarm on this?

BERGSTROM: Interestingly, we saw some loud voices early on coming from organized campaigns from political opponents of the Chinese government. There was both a lot of hyperbole but also some truth to what they were sharing. It was feeling like misinformation at the time, but turned out to be partially right. By mid-January, I was having a lot of conversations with others in the infectious disease community, but we didn't yet have diagnosed community transmission. By February, we knew it was a real problem.

FARR: What are some of the most concerning and prevalent hoaxes or false rumors that you're seeing? Can you share your top five?

CARL BERGSTROM: There's the idea that this virus is a Chinese bioweapon. Often (I've seen) a very quickly retracted paper referenced that claimed to have found big pieces of the HIV genome in the SARS-CoV-2 genome. That was debunked within 48 hours.Interestingly, a Chinese colleague told me that in China there is a very widely spread rumor on social media that it is a U.S. bioweapon, but I do not have documentation of this. There has been a lot of talk about the SO2 levels over Wuhan, linking it purportedly to the mass incineration of bodies. There is all the 5G stuff, but I haven't even gone down that rabbit hole. And there idea that Bill Gates is somehow involved, in creating and spreading the virus, not fighting it.

Finally, there were a rash of false second-hand narratives of catastrophes at hospitals. Some are spread by well known, credentialed people. I debunked one of those from the prominent neurologist on March 15th (The neurologist Scott Mintzer deleted an alarmist post after Bergstrom pointed out flaws with a second-hand account).

FARR: As a biologist, when did you first start to personally become concerned about COVID-19?

BERGSTROM: We have a mailing list for many of us professionals in the infectious disease world. You'll see clusters of disease every so often, which we'll share. In this case, we were concerned but the the information from China in those first months wasn't great. The bottom line is that by the time things got bad in Wuhan, infectious disease professionals knew that given the size of the city and the frequent travel to the rest of the world, it would get out. We didn't know if it would turn pandemic, because there have been cases where we've stamped out little fires as they emerge.

FARR: Could we have acted much sooner in the U.S., say in late January when the picture started to become more clear about how serious of a threat this was?

BERGSTROM: There was a denial and refusal to act that lost us some time, and that's part of what happened. But we also didn't have the resources in place to respond to a pandemic in terms of our coordination structure. There was definitely planning and investment that could have been done. I was most active in these sorts of discussions in the Bush years. During that period, there was a big debate about the role of government in public health and a reluctance to invest too heavily in pandemic planning. But I argued that there are some things the government has to provide. For me, that would include the research and surveillance tools, but also the infrastructure you need for rapid vaccine production.

FARR: So the government is really responsible, and not the private sector...

BERGSTROM: I'm not saying that the government should provide pandemic planning because I want a welfare state. There are some collective action problems that even the Chicago-school economists acknowledge will not be adequately solved by the market. No one expects us to raise a powerful standing army based on private market forces (and) we consider that a central role of the government to provide national defense. Pandemic preparedness is the same.

FARR: How come we were so unprepared for this, especially when it comes to having insufficient supplies of masks and personal protective equipment?

BERGSTROM: There's a 'not on my watchism,' which involves a choice between doing a politically unpopular thing to provide funding for pandemic preparedness that might not come, or avoid doing that and slash whatever is there. These are perceived as once-in-a-century catastrophes.

FARR: You've been researching pandemics throughout your career. Did you have a fear around respiratory viruses in particular?

BERGSTROM: I don't know why people don't talk more about the potential for a GI (gastrointestinal) pandemic. It's something I'm going to be asking about. I have also researched pox viruses. Monkeypox, with a few mutations, could become quite a bad thing. But it's these respiratory ones we keep seeing again and again. The story of the past twenty years has been SARS (severe acute respiratory syndrome), and all of these smaller outbreaks, and any one of them could have flared into a disaster. It made sense to expect that something like this COVID-19 pandemic could happen.

FARR: I've read some articles pointing to folks like Bill Gates who seemed to have seen this coming. Were they prescient, or just following the data?

BERGSTROM: Well, we had a pandemic 11 years ago (with H1N1). And there are others going back further in time. People forget the severity of the 1957 flu pandemic. There really isn't an excuse to be caught unprepared, but there's certainly no excuse going forward.

FARR: Now that we're here and we're in this, do we have some tough choices to make? Do you suspect that citizens are going to be asked to make tradeoffs when it comes to privacy and civil liberties? In China, you saw temperature checks of passers-by and at buildings, and other invasive surveillance measures.

BERGSTROM: Without widespread testing, even those measures won't be effective. My personal feeling is that we either have a long lockdown ahead of us, or we'll get testing capacity way up. With temperature checks, I suspect you'd miss a lot of asymptomatic cases so I'm really in two minds about it.

But another consideration is that we already allow ourselves to be tracked in unimaginable ways so that companies can sell ads. If it came to it, we might be asked to consider whether we'd be willing to be tracked via some surveillance measures to go back to work. I might opt in because I'm a public health professional with a secure job, but I completely understand why others wouldn't. And I don't think you can impose (surveillance systems) on people in the U.S.

FARR: You've tweeted about the IMHE model, which shows projections of the spread of COVID-19, assuming full social distancing. You've also shared some reservations with these predictions. Can you elaborate?

BERGSTROM: If you believe that model, things are looking pretty good in states like Washington State by mid-May. But this is all predicated on us being successful at turning the curve around. If we do manage to get reasonable testing going and we keep following the social distancing guidelines, these models suggest life could return to normal come the summer. But if we fall short in either of those things, then we're going to be looking at some harder choices about whether we let a lot of people get infected or consider a longer lockdown.

FARR: Do we have the political will to consider the longer quarantine?

BERGSTROM: I really have no idea. In this pandemic, we don't currently have pharmaceutical measures in place, like a proven treatment. What we do have is traditional public health. We have work stoppages, stay at home orders, travel restrictions. And we also have misinformation that undercuts the trust of scientists and other authorities. There's a political pressure that is building up on our policymakers. I do hope people will do everything they can to get us on the right trajectory, but I also want us to be aware and planning for all possible outcomes.

WATCH: Bill Gates believes schools could reopen in the fall

Continue reading here:
Biologist Carl Bergstrom on coronavirus, misinformation and why we weren't prepared - CNBC

Alector Announces FDA Fast Track Designation Granted to AL101 for the Treatment of Patients with Frontotemporal Dementia – Yahoo Finance

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AL101 for the treatment of patients with progranulin gene mutations causative of frontotemporal dementia (FTD-GRN). AL101, the companys second product candidate designed to restore progranulin levels in the brain, is currently being evaluated in a Phase 1 trial in healthy volunteers.

There is a clear and validated connection between progranulin expression in the brain and certain neurodegenerative disorders like FTD, Alzheimers disease and Parkinsons disease. At Alector, we are pioneering the development of therapies targeting the progranulin pathway, with two product candidates being tested in clinical trials, said Robert King, Ph.D., chief development officer at Alector. AL101 is the second product candidate from our progranulin program to receive Fast Track designation from the FDA, underscoring the need for new treatment options for these patients. We look forward to working with the agency to advance AL101 as quickly as possible.

Fast Track designation is designed to facilitate the development and expedite the review of therapies for serious conditions and fill an unmet medical need. Programs with Fast Track designation may benefit from early and frequent communications with the FDA, potential priority review, and additionally a rolling submission of the marketing application.

About AL101AL101 is Alector's wholly-owned human monoclonal antibody and second product designed to restore levels of progranulin in the central nervous system. Progranulin is a regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders. Mutations that moderately reduce the expression levels of progranulin have been shown to increase the risk of developing Alzheimers disease and Parkinsons disease, and increased progranulin levels have been demonstrated to be protective for these diseases in animal models.

Story continues

AL101 has the potential to be developed for the treatment of frontotemporal dementia, Alzheimers disease and Parkinsons disease. AL101 received orphan drug designation from the U.S. Food and Drug Administration for the treatment of frontotemporal dementia in July 2019 and Fast Track designation in February 2020.

About AlectorAlector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector is developing a broad portfolio of programs designed to functionally repair genetic mutations that cause dysfunction of the brains immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. The Companys product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimers disease. Alector is headquartered in South San Francisco, California. For additional information, please visit http://www.alector.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, the ability and timing for the closing of the public offering of common stock. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed offering, and other risks and uncertainties related to the offering, Alector and its business as set forth in Alectors registration statement on Form S-1 filed with the Securities and Exchange Commission (the SEC) on January 29, 2020 and the preliminary prospectus included therein, as well as the other documents Alector files from time to time with the SEC, including Alectors most recent Quarterly Report on Form 10-Q filed with the SEC on November 12, 2019. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alectors forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law.

Source: Alector, Inc.

Contacts

Media:1ABDan Budwick, 973-271-6085dan@1abmedia.comorInvestors:Alector, Inc.ir@alector.com

Read this article:
Alector Announces FDA Fast Track Designation Granted to AL101 for the Treatment of Patients with Frontotemporal Dementia - Yahoo Finance

Neurocognitive Conditions Among People Living With HIV – Infectious Disease Advisor

Neurologic conditionsassociated with HIV remain major contributors to morbidity and mortality, and are increasingly recognizedin the aging population of individuals living with HIV who are receiving long-standingcombination antiretroviral therapy (cART).

Neurologic complications are common among individuals who are not receiving treatment for HIV as a result of immunosuppression caused by the infection, but are also widely reported after establishing a treatment regimen. Although the advent of ART, and particularly cART, have successfully reduced the risk for progression of HIV-associated neurocognitive disorders (HAND), these therapies are not effective in all patients, and thus allow for the development of neurocognitive dysfunction.2 In addition, during the early stages of infection, HIV can readily enter the central nervous system (CNS), where a persistent reservoir of HIV infection and inflammation serves to re-infect healthy cells to produce symptoms of HAND, despite therapy.1,2 And finally, drug toxicity from cART may also contribute to the development of HAND.1,2

The Evolution of HAND

The majority of patients diagnosed with HIVare on continuing ART, which is widely recognized to offer a much extended lifeexpectancy to approximately the lifespan of people without HIV; however, asmany as one-half of patients also have neurocognitive dysfunction.1,3Prior to the ART era, HIV-associated dementia, the most severe form of HAND,was common in patients with AIDS and was generally irreversible, noted Deanna Saylor, MD, MHS, director of theHopkins Global Neurology Program at Johns Hopkins University School of Medicine inBaltimore, Maryland. In the ART era, the overallprevalence of HAND is unchanged, but we have seen a dramatic shift from themost severe forms to milder forms of HAND such as asymptomatic neurocognitiveimpairment and mild neurocognitive disorder. HAND is no longer a relentlesslyprogressive disease, she said.

Further, Justin C McArthur, MBBS, MPH, director of the department of neurology at Johns Hopkins Hospital and founding director the of the Johns Hopkins/National Institute of Mental Health Research Center for Novel Therapeutics of HIV-associated Cognitive Disorders in Baltimore, Maryland, has observed that as many as 50% of the current population living with HIV is now aged >50 years, and living with the infection as a long-term condition, putting them at risk for a potentially milder form of a combination of HIV- and age-related cognitive impairment. Because of the potency of antiretrovirals and the strategies to treat everyone as early as possible, the spectrum of HIV-associated neurocognitive dysfunction has really shifted from what could be a severe disease with frank dementia and neurologic depth to a much milder type of disorder that is really analogous to [mild cognitive impairment] outside the disease spectrum,he said.

DrMcArthur coauthored a 2019 study by Dastgheyb et al4 thatdistinguished 4 phenotypes of neurocognitive dysfunction, including verbalfluency, executive function, learning and recall, and motor function. Thissmall study of 38 women helps to illuminate that HAND is not stereotypic fromone individual to another, he observed, and contains variations which may beexplainable by where the virus is in the brain or by other inherentcharacteristics of the patient, such as traumatic brain injury of acceleratedvascular disease.

HIV Reservoir in the Brain

Oneof the ongoing challenges to effective treatment of HAND is the discovery thatthe brain may serve as a reservoir for HIV replication, even when systemicviral suppression has been achieved.2,5 We know that HIV DNA can beisolated from the spinal fluid, even in individuals who are on antiretroviralsand it suggests that there is still perhaps a small but still quite importantreservoir of HIV within the central nervous system, Dr McArthur pointed out,which explains how a recurrent reseeding of infection from the brain can keepthe virus alive despite effective therapy.

Monocyte Activation

Itnow appears that a core driver for the development of HAND is cellularactivation of monocytes, macrophages, and microglia in the brain. High levelsof monocyte activation have been reported in patients with long-standing HIVmanaged by cART. The COBRA study of 134 PLHIV on cART and 79 non-HIV-infectedcontrols reported plasma markers showing high levels of monocyte activation,inflammation, and intestinal damage in the HIV cohort that were all predictiveof mortality and morbidity in treated HIV patients. At the same time, systemicT-cell activation in HIV did not have predictive value.6,7

Monocytes are cells that circulate in the blood and occasionally are found in the , but we think most of the reservoir in the brain and in the meninges are actually in tissue macrophages and in the microglia, Dr McArthur explained. These are cells that tend not to migrate. They dont move around like monocytes, they just sit there, but they can potentially induce or spread infection to other cells that are moving past them. As the mobile cells continue to travel, the infection is reintroduced into the spinal fluid, lymphatic circulation, and back into the blood, he added.

Areas for Future Research

Newavenues of research that aim to explore potential eradication of the virus byfirst eliminating the CNS reservoir are needed, Dr Saylor noted, as well as thedevelopment of treatments that fully normalize systemic and CNSinflammation.Current ART regimens reduce but do not normalize systemicand CNS inflammation, and we believe many of the non-infectious complicationsof chronic HIV infection are related to persistent low levels of inflammation,including stroke, dementia and other systemic complications, she said. Moreover,she pointed to the need for new more effective treatments to improve existingHIV-associated cognitive impairment.

DrMcArthur also highlighted that the dynamics of how the virus is produced andeliminated in specific cell types such as macrophages and microglia is quitedifferent than in the major cellular target in the body, the T-lymphocyte. Weneed to understand much more about the viral dynamics in the central nervoussystem, he said.

References

1. Saylor D, Dickens AM, Sacktor N, et al. HIV-associated neurocognitive disorderpathogenesis and prospects for treatment. Nat Rev Neurol. 2016;12(4):234-48.

2. D Saylor. Neurologic Complications of Human Immunodeficiency Virus Infection.

Continuum (Minneap Minn)2018;24:1397-1421.

3. Nightengale S, Winston A, Letendre S, et al. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014;13:1139-1151.

4. Dastgheyb RM, Sacktor N, Franklin D, et al. Cognitive Trajectory Phenotypes in Human Immunodeficiency Virus-Infected Patients.J Acquir Immune Defic Syndr. 2019;82:6170.

5. Wong ME, Jaworowski A, Hearps AC. The HIV Reservoir in Monocytes and Macrophages Front Immunol. 2019;10:1435. doi:10.3389/fimmu.2019.01435

6. Booiman T, Wit FW, Maurer I, et al. High Cellular Monocyte Activation in People Living With Human Immunodeficiency Virus on Combination Antiretroviral Therapy and Lifestyle-Matched Controls Is Associated With Greater Inflammation in Cerebrospinal Fluid. Open Forum Infect Dis. 2017;4:ofx108.

7. Wright EJ, Thakur KT, Bearden D, Birbeck GL. Global developments in HIV neurology. Handb Clin Neurol. 2018;152:265-287.

Excerpt from:
Neurocognitive Conditions Among People Living With HIV - Infectious Disease Advisor

Neurovascular or Interventional Neurology Devices Market Business Opportunities, Current Trends and Growth Forecasts by 2025 | Stryker, Medtronic,…

Chicago, United States: The global Neurovascular or Interventional Neurology Devices Market is expected to surge at a steady CAGR in the coming years, states the latest Report Hive Research. The publication offers an insightful take on the historical data of the market and the milestones it has achieved. The report also includes an assessment of current market trends and dynamics, which helps in mapping the trajectory of the global Neurovascular or Interventional Neurology Devices market. Analysts have used Porters five forces analysis and SWOT analysis to explain the various elements of the market in absolute detail. Furthermore, it also studies the socio-economic factors, political changes, and environmental norms that are likely to affect the global Neurovascular or Interventional Neurology Devices market.

The Neurovascular or Interventional Neurology Devices market study published in the report is in a chapter-wise format to ease of the readability and complexity of the data covered. Each chapter is further categorized into its respective segments containing well-structured data. The competitive scenario displayed includes major market player details such as, company profile, end-user demand, import/export volume, sales data, etc. The report also covers the business strategies applied by different players, which will be a great addition for smart business decisions.

Get a Sample PDF Report: https://www.reporthive.com/request_sample/2258380

Top Key players cited in the report:

StrykerMedtronicJohnson and JohnsonTerumoPenumbraBoston ScientificAbbott LaboratoriesMerit Medical SystemsMicroport Scientific

The report on Neurovascular or Interventional Neurology Devices market provides qualitative as well as quantitative analysis in terms of market dynamics, competition scenarios, opportunity analysis, market growth, industrial chain, etc. In this study, 2019 has been considered as the base year and 2020 to 2026 as the forecast period to estimate the market size for Neurovascular or Interventional Neurology Devices.

The research report is committed to giving its readers an unbiased point of view of the global Neurovascular or Interventional Neurology Devices market. Thus, along with statistics, it includes opinions and recommendation of market experts. This allows the readers to acquire a holistic view of the global market and the segments therein. The research report includes the study of the market segments on the basis of type, application, and region. This helps in identifying segment-specific drivers, restraints, threats, and opportunities.

The scope of the Report:The research report on the global Neurovascular or Interventional Neurology Devices market is a comprehensive publication that aims to identify the financial outlook of the market. For the same reason it offers a detailed understanding of the competitive landscape. It studies some of the leading players, their management styles, their research and development statuses, and their expansion strategies.

The report also includes product portfolios and the list of products in the pipeline. It includes a through explanation of the cutting-edging technologies and investments being made to upgrade the existing ones.

Global Neurovascular or Interventional Neurology Devices Market: Competitive RivalryThe chapter on company profiles studies the various companies operating in the global Neurovascular or Interventional Neurology Devices market. It evaluates the financial outlooks of these companies, their research and development statuses, and their expansion strategies for the coming years. Analysts have also provided a detailed list of the strategic initiatives taken by the Neurovascular or Interventional Neurology Devices market participants in the past few years to remain ahead of the competition.

Global Neurovascular or Interventional Neurology Devices Market: Regional Segments

The chapter on regional segmentation details the regional aspects of the global Neurovascular or Interventional Neurology Devices market. This chapter explains the regulatory framework that is likely to impact the overall market. It highlights the political scenario in the market and the anticipates its influence on the global Neurovascular or Interventional Neurology Devices market.

Neurovascular or Interventional Neurology Devices Segmentation by Product

Cerebral Thrombectomy DevicesCarotid Artery Stenting (CAS) SystemCerebral Aneurysm and AVM Endovascular Embolization SystemsIntracranial Stent SystemsFlow Diverter for Aneurysm

Neurovascular or Interventional Neurology Devices Segmentation by Application

HospitalClinic

Get Customized PDF template of this report: https://www.reporthive.com/request_customization/2258380

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Neurovascular or Interventional Neurology Devices market

Chapter 2: Evaluating the leading manufacturers of the global Neurovascular or Interventional Neurology Devices marketwhich consists of its revenue, sales, and price of the products

Chapter 3: Displaying the competitive nature among key manufacturers, with market share, revenue, and sales

Chapter 4: Presenting global Neurovascular or Interventional Neurology Devices marketby regions, market share and with revenue and sales for the projected period

Chapter 5, 6, 7, 8 and 9: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions

Speak to Research Analyst: +1-312-604-7084

About Us:Report Hive Research delivers strategic market research reports, statistical survey, and Industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of United States Business Leaders, Government Organizations, SMEs, Individual and Start-ups, Management Consulting Firms, and Universities etc. Our library of 600,000+ market reports covers industries like Chemical, Healthcare, IT, Telecom, Semiconductor, etc. in the USA, Europe Middle East, Africa, Asia Pacific. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio and application analysis etc.

Read more:
Neurovascular or Interventional Neurology Devices Market Business Opportunities, Current Trends and Growth Forecasts by 2025 | Stryker, Medtronic,...

Exploring the neurology of motivation – Medical News Bulletin

Have you ever wondered how animals look or hunt for food? The simple response is they just follow their instincts, but what are the mechanisms behind their bodys response to look for food, and keep looking until they are satisfied? What is behind the neurology of motivation?

Previous research has found that environmental gustatory cues would provide information about the type and quality of available food, but only internal nutrient levels would ultimately suppress the circuits to the neurology of motivation. An international team of researchers led by the scientists from the Technical University of Munich set up various experiments involving the common fruit fly to determine which sensory cues are prioritized to influence a mammalian animals behaviour and internal motivation.

Both hungry and fed flies were tethered to a spherical treadmill and exposed to an odour source as a repeated stimulus. The activity of the flies was recorded at various intervals such as pre- and post-stimulus and then categorized into levels of motivation.

The researchers found two sets of behaviours during odour stimulation. Upon exposure, the flies sped up to almost double their average speed and suppressed turning behaviour to head straighter. This suggested that they were tracking the odour stimulus and had increased motivation. When the stimulation was terminated, the flies significantly reduced their speed and almost stopped before regaining the average speed. They also increased their turning behaviour, which was attributed to them searching for the initial odour stimulus.

Over the span of 10 repeated trials, the researchers further identified an evolution in the flies behaviour. The acceleration in speed upon stimulus onset had gradually increased and turning behaviour was more efficiently suppressed. In the end, the data provided insight into the flies neurology of motivation as the behaviour to track food was significantly intensified over the course of the experiment.

In addition, the researchers conducted experiments to investigate any changes in the flies behaviour induced by their hunger state. Flies were not intrigued or motivated to track odours when they were fed. However, those who were starved for 24 and 48 hours almost doubled their speed as well as tracking time when exposed to the odour stimulus. This demonstrated that starvation time was correlated with both tracking speed and time. The longer the flies were starved, the longer and faster they pursued the food odour.

The results published in CellPress identified two neurotransmitters that were key to the neurology of motivation in mammals: norepinephrine and octopamine. By taking advantage of the smaller and simpler structure in a fly brains neural network, the researchers found it easier to sift and identify specific neurons and their function. The presence of octopamine led to flies immediately slowing down or even stopping their odour tracking, whereas the presence of dopamine significantly increased their tracking speed and consequently, motivation.

The conclusions drawn from the study identified the circuit significant to the neurology of motivation that influenced the flies behaviour based on a need- and state-dependent manner. As similar neurotransmitters and circuits exist in the human mammalian brain, the hope of the study was to further understand mechanisms and one day, understand and treat human conditions such as addiction.

Written by Stephanie Tsang

References:

Sayin, Sercan, et al. A Neural Circuit Arbitrates between Persistence and Withdrawal in Hungry Drosophila.Neuron, vol. 104, no. 3, 27 Aug. 2019, doi:10.1016/j.neuron.2019.07.028.

Battenberg, Andreas. The Secret of Motivation.EurekAlert!, 26 Sept. 2019, http://www.eurekalert.org/pub_releases/2019-09/tuom-tso092619.php.

Image byluvqsfromPixabay

Follow this link:
Exploring the neurology of motivation - Medical News Bulletin

IPN Solutions Launches with New Portfolio of Programs and Technology Platforms – BioSpace

Specialty practices who are members of IPN Solutions can leverage technology, services, and informatics to drive higher-quality and lower-cost care in their community. Some of the programs and technology platforms offered through IPN Solutions include:

In this dynamic GPO environment, our customers have an abundance of choices with how they support their patient care model. At IPN Solutions, our goal is to provide the tools specialty practices need to elevate their business, maintain operational efficiency, and support value-based care models that rely on patient satisfaction and engagement, Brian Ansay, President Specialty Physician Group Purchasing, AmerisourceBergen. Now with IPN Solutions, existing members and those that join us will have direct access to a dedicated team support structure, including strategic account managers, directors, and administrators who will assist with maximizing operational efficiencies and contract opportunities, as well as integrating solutions into their practices.

For more than 20 years, IPN supported physicians in their mission to provide better patient care through contract pricing on pharmaceuticals and clinical and operational education. IPN Solutions will now provide that same support, but with augmented and wrap-around technology, programs and service offerings. IPN Solutions supports neurology, rheumatology, ophthalmology, retina, gastroenterology, dermatology, and urology practices. Visit http://www.ipnonline.com for more information on IPN Solutions.

About IPN Solutions

A company of AmerisourceBergen, IPN Solutions is a national specialty network that provides GPO drug contracting, educational programming, practice solutions and services, and advocacy support to neurology, rheumatology, ophthalmology, retina, gastroenterology, dermatology, and urology practices. Created for physicians and healthcare professionals, IPN has developed relationships with drug manufacturers and service providers to help reduce costs to providers. IPN members enjoy GPO contracting on pharmaceuticals, diagnostic testing, surgical equipment, and medical equipment. As a member of IPN, specialty practices can share in the networks purchasing power, while remaining an independent and autonomous entity. Learn more at ipnonline.com.

About AmerisourceBergen

AmerisourceBergen provides pharmaceutical products, value-driving services, and business solutions that improve access to care. Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the pharmaceutical supply chain. Global manufacturers depend on us for services that drive commercial success for their products. Through our daily work and powered by our 21,000 associates we are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500, with more than $160 billion in annual revenue. The company is headquartered in Valley Forge, Pa. and has a presence in 50+ countries. Learn more at amerisourcebergen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200204005260/en/

See original here:
IPN Solutions Launches with New Portfolio of Programs and Technology Platforms - BioSpace

Headache and Migraine: Short- and Long-Term Effects of Medical Cannabis – Neurology Advisor

Headache and migraine ratings were reduced by approximately50% after use of medical cannabis, and these reductions were greater in mencompared with women, according to study results published in The Journal of Pain. Although there wasevidence for the development of tolerance to cannabiss effects on headache,there was no evidence for medication overuse headache.

Even though cannabis is commonly used to alleviate headache and migraine, sparse research exists on its effectiveness. The current study was designed to evaluate if cannabis inhalation decreases ratings for migraine and headache and to assess how sex, cannabis type (flower vs concentrate), cannabidiol (CBD), tetrahydrocannabinol (THC), or dose may contribute to these changes and to any evidence of tolerance to effects. Investigators obtained study data from Strainprint, a medical cannabis mobile application allowing patients to track symptoms before and after use of different cannabis strains and doses. They used models to analyze data from 12,293 sessions of 1306 medical cannabis users tracking headache treatment and from 7441 sessions of 653 medical cannabis users tracking migraine treatment.

When researchers examined changes by sex, men reported significantly more sessions with headache reduction compared with women (90.9% vs 89.1%, respectively; 2(1)=10.87;P=.001). Also, women reported significantly more sessions with headache exacerbation (ie, worsening symptoms) compared with men (2.9% vs 1.8%, respectively; 2(1)=16.28;P<.001). Researchers did not determine any sex differences for the percentage of sessions with no change in severity of headache (women, 8.1% vs men, 7.4%; 2(1)=2.03;P=.15). For migraines, they observed no significant differences between men and women in symptom reduction (87.3% vs 88.6%, respectively; 2(1)=2.47,P=.12) or exacerbation (2.9% vs 3.2%, respectively; 2(1)=0.62;P=.43), but significantly more men reported no change in migraine severity (9.9% vs 8.2%, respectively; 2(1)=5.5;P=.02).

The use of a concentrate was associated with greaterreductions in headache ratings compared with the use of flower (=0.0902;P<.001), and there were no maineffects in any of the models associated with CBD concentration, THCconcentration, or dose. Investigators found evidence of tolerance, indicated bylater headache episodes associated with a lesser symptom decrease compared withearlier episodes (=0.130.05;P=.01).

Despite the study limitations, which included possiblesampling bias and the lack of a placebo control group, the study investigatorsconcluded that medical cannabis can reduce migraine and headache ratings byapproximately 50%. Although evidence shows that regular use may producetolerance, cannabis does not lead to the medication overuse headache thatis associated with other conventional treatments, meaning that use of cannabisdoes not make headaches or migraines worse over time. Future double-blind,placebo controlled clinical trials are warranted and will help to rule outplacebo effects and provide a more controlled examination of dose, type ofcannabis, THC, CBD, and THC CBD interactions.

Reference

Cuttler C, Spradlin A, Cleveland MJ, Craft RM.Short- and long-term effects of cannabis on headache and migraine[published online November 9, 2019].J Pain. doi:10.1016/j.jpain.2019.11.001

Go here to see the original:
Headache and Migraine: Short- and Long-Term Effects of Medical Cannabis - Neurology Advisor

Neurological program at the U or R giving participants a new sense of hope – Global News

Twenty-seven years ago Barb Butler was involved in a car crash that left her in a coma for 21 days. She has been dealing with a traumatic brain injury ever since.

I had to learn to walk [again], I had to learn to read, Butler said.

In September, Butler joined the Enrich program at the University of Regina a relatively new program providing rehabilitation to those with Parkinsons disease and other neurological conditions.

Enrich gives clients the chance to be active, through tasked-oriented movement activities. Things like reaching and grasping, handwriting, walking and stepping up and downstairs.

In general day-to-day activities, I would often be afraid I was going to fall and now I dont even think about it anymore because my balance has improved that much, Butler said.

Story continues below advertisement

Cameron Mang is an assistant professor in Kinesiology and Health Studies at the U of R and the founder of Enrich.

I definitely felt there was a need for this type of work here and I was really excited to see how interested the community was, Mang said.

The results have been fascinating, he said.

Weve seen improvements in walking functions and endurance, some strength improvements and some balance improvements, Mang explained.

A lot of people just comment they feel the social interaction really helps them in their lives as well.

The Enrich program began in the fall and has 11 members.

Allan Johnson has been attending since it started. He was diagnosed with Parkinsons disease three years, but has been dealing with symptoms for about 20 years.

My biggest accomplishment is I have been able to write or actually print legibly in block capitals for the first time in quite a few years, Johnson said.

I have exercises stretching to do with my hands that allow me to build dexterity and get a little more control over them.

Enrich runs twice a week at the U of Rs fitness centre. For more information visit their website.

Story continues below advertisement

2020 Global News, a division of Corus Entertainment Inc.

Originally posted here:
Neurological program at the U or R giving participants a new sense of hope - Global News

Fulcrum Therapeutics Announces Multiple Presentations at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform -…

CAMBRIDGE,Mass., May 21, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced multiple presentations at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform.AANs annual meeting was cancelled due to COVID-19 and the virtual platform allows for all accepted oral and poster presentations to be presented.The materials linked below willbe available for approximately10 months.

We are pleased by the breadth of losmapimod data selected for presentation, which highlights the progress weve made to develop a treatment for patients with facioscapulohumeral muscular dystrophy (FSHD) and our approach to treating the root cause of genetically defined rare diseases, saidDiego Cadavid, M.D., Fulcrums senior vice president, clinical development. In particular, we have identified a set of stable DUX4-regulated gene transcripts that provide a pharmacodynamic biomarker endpoint to measure the treatment effect of losmapimod in FSHD. Additionally, in collaboration with AMRA Medical, we have created a standardized whole-body magnetic resonance imaging (MRI) protocol to evaluate skeletal muscle composition in FSHD patients. I would like to thank the patients and their families who have participated in our trials, and who inspire us every day.

2020 AAN Virtual Platform Presentation and Poster Details

Phase 1 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD): Safety, Tolerability, and Target Engagement

https://cslide-us.ctimeetingtech.com/aan2020/attendee/eposter/poster/2192

Design of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Subjects with Facioscapulohumeral Muscular Dystrophy (FSHD): ReDUX4

https://cslide-us.ctimeetingtech.com/aan2020/attendee/eposter/poster/2193

Development of an Optimized Timed Up and Go (oTUG) for Measurement of Changes in Mobility Impairment in Facioscapulohumeral Muscular Dystrophy (FSHD) Clinical Trials

https://cslide-us.ctimeetingtech.com/aan2020/attendee/eposter/poster/1638

A Biomarker of DUX4 Activity to Evaluate losmapimod Treatment Effect in FSHD Phase 2 Trials

https://cslide-us.ctimeetingtech.com/aan2020/attendee/eposter/poster/2196

An In-Home Study of Facioscapulohumeral Muscular Dystrophy (FSHD) Patients using Contactless Wireless Sensing and Machine Learning

https://cslide-us.ctimeetingtech.com/aan2020/attendee/eposter/poster/1721

Development and Evaluation of a Whole-body MRI Imaging Protocol and Analysis Algorithms to Measure Changes in Skeletal Muscle in FSHD

https://cslide-us.ctimeetingtech.com/aan2020/attendee/eposter/poster/2176

About FSHDFSHD is characterized by progressive skeletal muscle loss that initially causes weakness in muscles in the face, shoulders, arms, and trunk, and progresses to weakness throughout the lower body. Skeletal muscle weakness results in significant physical limitations, including an inability to smile and difficulty using arms for activities, with many patients ultimately becoming dependent upon the use of a wheelchair for daily mobility.

FSHD is caused by mis-expression of DUX4 in skeletal muscle, resulting in the presence of DUX4 proteins that are toxic to muscle tissue. Normally, DUX4-driven gene expression is limited to early embryonic development, after which time the DUX4 gene is silenced. In people with FSHD, the DUX4 gene is turned on as a result of a genetic mutation. The result is death of muscle and its replacement by fat, leading to skeletal muscle weakness and progressive disability. There are no approved therapies for FSHD, one of the most common forms of muscular dystrophy, with an estimated patient population of 16,000 to 38,000 in the United States alone.

About Losmapimod Losmapimod is a selective p38/ mitogen activated protein kinase (MAPK) inhibitor that was exclusively in-licensed from GSK by Fulcrum Therapeutics following Fulcrums discovery of the role of p38/ inhibitors in the reduction of DUX4 expression and an extensive review of known compounds. Utilizing its internal product engine, Fulcrum discovered that inhibition of p38/ reduced expression of the DUX4 gene in muscle cells derived from patients with FSHD. Although losmapimod has never previously been explored in muscular dystrophies, it has been evaluated in more than 3,500 subjects in clinical trials across multiple other indications, including in several Phase 2 trials and a Phase 3 trial. No safety signals were attributed to losmapimod in any of these trials. Fulcrum is currently conducting Phase 2 trials investigating the safety, tolerability, and efficacy of losmapimod to treat the root cause of FSHD.

About Fulcrum TherapeuticsFulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrums proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and has completed extensive pre-clinical research for FTX-6058 for the treatment of sickle cell disease and beta-thalassemia.

Please visit http://www.fulcrumtx.com.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the development status of the Companys product candidates. All statements, other than statements of historical facts, contained in this press release, including statements regarding the Companys strategy, future operations, future financial position, prospects, plans and objectives of management, are forward-looking statements. The words anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, project, should, target, will, would and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with Fulcrums ability to obtain and maintain necessary approvals from the FDA and other regulatory authorities; continue to advance its product candidates in clinical trials; replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of losmapimod and its other product candidates; advance the development of its product candidates under the timelines it anticipates in current and future clinical trials; obtain, maintain or protect intellectual property rights related to its product candidates; manage expenses; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Companys actual results to differ from those contained in the forward-looking statements, see the Risk Factors section, as well as discussions of potential risks, uncertainties and other important factors, in the Companys most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Companys views as of the date hereof and should not be relied upon as representing the Companys views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Companys views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

Contact:

Investors: Christi Waarich Director, Investor Relations and Corporate Communications617-651-8664cwaarich@fulcrumtx.com

Stephanie Ascher Stern Investor Relations, Inc.stephanie.ascher@sternir.com 212-362-1200

Media: Kaitlin GallagherBerry & Company Public Relationskgallagher@berrypr.com212-253-8881

Here is the original post:
Fulcrum Therapeutics Announces Multiple Presentations at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform -...

100 hospitals and health systems with great neurosurgery and spine programs | 2019 – Becker’s Hospital Review

Becker's Healthcare named the following organizations to the 2019 edition of its list "100 hospitals and health systems with great neurosurgery and spine programs."

The organizations featured on this year's list have extensive neurosurgery and spine programs, providing treatment and cutting edge research into brain and spine disorders. Many hospitals and health systems featured have earned top honors for medical excellence, outcomes and patient experience in their spine and brain surgery departments.

To develop this list, the Becker's Healthcare editorial team examined national rankings and awards for neurosurgery and spine care. The editorial team examined U.S. News & World Report national rankings for neurology and neurosurgery; CareChex national and regional rankings for neurological care and Blue Distinction Center for Spine Surgery designation to develop this list. Please contact Laura Dyrda at ldyrda@beckershealthcare.com with any questions about this list.

Note: Hospitals cannot pay for inclusion on this list. Organizations are presented in alphabetical order.

Abbott Northwestern Hospital (Minneapolis). At Abbott Northwestern Hospital's Spine Institute, physicians treat more than 4,000 patients annually. The hospital has been designated as a Blue Distinction Center for Spine Surgery by BlueCross BlueShield of Minnesota. With five area partners, Abbott Northwestern Hospital was ranked on U.S. News & World Report's list of 50 best hospitals for neurology and neurosurgery in 2019-20.

AdventHealth Orlando (Fla.). AdventHealth's Neuroscience Institute provides comprehensive care to patients with brain and spinal disorders. The health system's brain tumor team includes 12 physicians, and the spine team features 15 physicians that aim to stay at the forefront of spinal treatment. With an elite team, U.S. News & World Report ranked AdventHealth Orlando among the 50 best hospitals for neurology and neurosurgery for 2019-20.

Ascension Seton (Austin, Texas). Physicians at Ascension Seton's Brain & Spine Institute specialize in minimally invasive and complex surgery for patients suffering from problems with their brain, spine, cerebrovascular system and peripheral nerves. Spine, orthopedic and neurosurgeons at the hospital have been recognized nationally and internationally for pioneering new treatments and research. The Seton Brain & Spine Institute has five locations offering neurosurgery across Texas.

Atrium Health (Charlotte, N.C.). Atrium Health offers one of the region's largest neurosurgery specialty programs. The health system's spine institute has been recognized by Blue Cross Blue Shield as a Blue Distinction Center for its quality care and outcomes. An early adopter of minimally invasive and robotic surgery, Atrium Health's Neurosciences Institute has 20-plus years of groundbreaking investigator-initiated and industry-sponsored clinical trials.

Barnes-Jewish Hospital/Washington University School of Medicine (St. Louis). The Barnes-Jewish & Washington University Spine Center receives patient referrals from all around the world. As a result, it has grown into one of the largest clinical spine practices in the nation. U.S. News & World Report ranked Barnes-Jewish Hospital and Washington University School of Medicine among the top 50 hospitals in the nation for neurology and neurosurgery, and the top hospital in Missouri for those specialties in 2019-20.

Barrow Neurological Institute (Phoenix). Physicians at Barrow Neurological Institute oversee more than 8,000 admissions and perform more than 5,000 neurosurgeries annually more than anywhere else in the U.S. There are 26 neurosurgeons, nine neurosurgery fellows and 28 neurosurgery residents on staff at the hospital. As one of the leading spine organizations in the world, U.S. News & World Report named Barrow Neurological Institute among the top 50 hospitals in the nation for neurology and neurosurgery in 2019-20.

Baptist Medical Center Jacksonville (Fla.). Surgeons at Baptist Medical Center have teamed up with Baptist MD Anderson Cancer Center in Jacksonville to conduct clinical trials related to brain and spine tumors. Along with its extensive brain and spine tumors division, Baptist Medical Center Jacksonville has a robust stroke and cerebrovascular care team and four neurologic oncologists. Neurosurgeons at the hospital's Stroke & Cerebrovascular Center are participating in more than 20 ongoing clinical trials.

Baylor St. Luke's Medical Center (Houston). Baylor St. Luke's Medical Center created its Neurosciences Institute in 2013, and it has since has been accredited by DNV GL Healthcare as a certified comprehensive stroke center. Baylor St. Luke's Medical Center neurosurgeons have also helped the hospital receive the Gold Plus Quality Achievement Award from the American Stroke Association. Baylor St. Luke's Medical Center was recognized in 2019-20 by U.S. News & World Report as one of the best hospitals in the nation for neurology and neurosurgery.

Beaumont Health (Southfield, Mich.). Beaumont Health was the first hospital in Michigan to create a pediatric stereo-EEG epilepsy surgery program to pinpoint seizures and cure drug-resistant epilepsy. The hospital's neurosurgery team is researching stem cell regeneration and spine reconstruction. Additionally, as a leading hospital for orthopedic surgery, neurosurgery and neurology, Beaumont Health has a leading spine team with on-call surgeons who can be at the hospital in 15 minutes no matter the time of day.

Beth Israel Deaconess Medical Center (Boston). All physicians at Beth Israel's Spine Center are board-certified and faculty of Boston-based Harvard Medical School. In total, there are four neurosurgeons and three orthopedic spine surgeons. To make care more accessible, Beth Israel Deaconess Medical Center has opened six spine centers throughout Massachusetts that provide comprehensive care patients in Boston and the surrounding area.

Boston Children's Hospital. The spine division of Boston Children's Hospital collaborates with the hospital's department of neurosurgery to treat complex spine conditions. Boston Children's Hospital has a complex cervical spine program as well as a spine and sports program. As a leading hospital for orthopedics and spine in the U.S., Boston Children's has various study groups, including a spinal deformity group whose Scoliosis Outcomes Database is cited in more than 45 abstracts and 15 peer-reviewed publications annually. In 2019-20, U.S. News & World Report ranked Boston Children's No. 1 in the nation for pediatric neurology and neurosurgery.

Brigham and Women's Hospital (Boston). The Comprehensive Spine Center at Brigham and Women's Faulkner Hospital brings together neurosurgeons, orthopedic surgeons, and specialists in pain management, physical medicine and rehabilitation. Brigham and Women's Hospital has five other spine centers throughout Massachusetts. U.S. News & World Report ranked the hospital among the top 20 in the nation for neurology and neurosurgery in 2019-20.

Carilion Clinic (Roanoke, Va.). The 1,026-bed Carilion Clinic hospital system provided care to nearly 1 million residents of Virginia and West Virginia in 2018. Touting around 13,320 employees and nine hospitals, the health system has 732 physicians across 77 specialties. Surgeons at Carilion's Institute for Orthopaedics and Neurosciences perform approximately 300 minimally invasive spine procedures annually, and it has the region's only deformity correction program for both adult and pediatric patients.

Cedars-Sinai Medical Center (Los Angeles). Serving more than 1 million patients annually at more than 40 locations, Cedars-Sinai Medical Center has more than 4,500 physicians on staff. The Cedars-Sinai spine team has 26 spine surgeons, assisted by eight advanced care providers. The health system is active in research efforts, hosting an array of clinical trials. Cedars-Sinai splits its spine care between four locations, including the Cedars-Sinai Spine Center and the Cedars-Sinai Kerlan-Jobe Institute. U.S. News & World Report ranked Cedars-Sinai as the No. 12 hospital for neurology and neurosurgery for 2019-20.

Cincinnati Children's Hospital Medical Center. Established in 1883, Cincinnati Children's Hospital Medical Center has more than 600 beds and around 1.3 million patient encounters in fiscal year 2017. The hospital's Crawford Spine Center was recognized by U.S. News & World Report as among the best hospitals for pediatric neurology and neurosurgery for 2019-20. The hospital is also involved in spine research, focusing on endoscopic technology, scoliosis correction and guided spine growth.

Cleveland Clinic. Featuring both a robust clinical program and a comprehensive spine research lab, Cleveland Clinic's Center for Spine Health sees thousands of patients annually. The Center for Spine Health has three specialty departments to address lower back pain, spinal deformity and spine tumors. Cleveland Clinic has 14 spine surgeons on staff, 14 medical/interventional staff members and 13 advanced care providers in its Center for Spine Health. The center is also testing robotics and is in the midst of a cervical spondylotic myelopathy surgical trial. U.S. News & World Report ranked Cleveland Clinic No. 10 in the nation for neurology and neurosurgery in 2019-20.

Dartmouth-Hitchcock Medical Center (Lebanon, N.H.). Dartmouth-Hitchcock developed its Center for Pain and Spine to meet the needs of its patient population, which comprises about 1.9 million people across northern New England. Anthem BlueCross BlueShield named the center a Blue Distinction Center for Spine Surgery for its commitment to good patient outcomes. U.S. News & World Report recognized the hospital as the highest performing neurosurgery institute in New Hampshire in 2019-20.

Duke University Hospital (Durham, N.C.). Duke University Hospital's comprehensive spine institute has 106 physicians on hand to provide an array of spine-related treatments. The spine team at Duke performs more than 1,200 spine surgeries annually. The hospital equipped all its surgery centers with intraoperative imaging equipment to ensure all procedures and physicians have access to real-time imaging information. U.S. News & World Report named Duke its No. 1 hospital in North Carolina and among the top 25 hospitals in the nation for neurology and neurosurgery in 2019-20.

Emory University Hospital (Atlanta). With its six locations throughout Atlanta, Emory University Orthopaedics & Spine Hospital offers patients comprehensive treatment options. Emory's neuroscience program will soon be headlined by the Emory Musculoskeletal Institute in Brookhaven, Ga. The institute broke ground in October 2019 and will be a 180,000-square-foot center dedicated to spine care. Emory University Hospital planners incorporated several environmentally conscious features into the institute. U.S. News & World Report ranked Emory among the top 50 hospitals in the nation for neurology and neurosurgery in 2019-20.

Froedtert & the Medical College of Wisconsin (Milwaukee). Froedtert & the Medical College of Wisconsin is the region's only academic regional medical center. Froedtert physicians see patients across the greater Milwaukee suburbs. Froedtert has four locations that specialize in spine care, including the outpatient clinic SpineCare. In 2017, Froedtert physicians treated 8,606 patients through its neurosurgery program.

Geisinger (Danville, Pa.). Founded more than a century ago, Geisinger has provided care to central Pennsylvania residents for generations. At the forefront of its neuroscience program is the Geisinger Neuroscience Institute. Employing a combination of treatment methods including microsurgery, minimally invasive surgery, robotic surgery and image-guided surgery, Geisinger has 24 providers on its neurosurgery staff. The health system is also on the forefront of innovation in healthcare delivery, with its ProvenCare program offering refunds to spine patients dissatisfied with their care. Geisinger is also a Walmart spine center of excellence, meaning the retail giant sends patients from across the country to undergo spinal evaluation and surgery at the health system.

Hackensack (N.J.) University Medical Center. Hackensack University Medical Center offers a robust program for neurosurgery care, including the Orthopedic Institute, which has more than 50 physicians on staff. Healthgrades has recognized Hackensack University Medical Center with its Cranial Neurosurgery Excellence Award for the last four years, and U.S. News & World Report ranked Hackensack as high performing for neurology and neurosurgery in 2019-20.

Henry Ford Hospital (Detroit). With more than 35 physicians specializing in spine and related specialties on staff, Henry Ford draws patients in Detroit and its greater suburban locations to its Henry Ford Spine Centers. In 2017 alone, Henry Ford surgeons performed some 75,000 surgeries across its 200 care sites. U.S. News & World Report ranked Henry Ford among the top 50 hospitals in the nation for neurology and neurosurgery in 2019-20.

Hoag Health Network (Newport Beach, Calif.). Hoag Health Network offers numerous spine programs, including care at Hoag Orthopedic Institute. In 2018, the institute reported 3,246 hospital spine procedures, as well as 180 ambulatory procedures. Hoag has two acute care hospitals, 11 urgent care centers and eight health centers it staffs with a team of more than 1,700 physicians and 6,000 employees. U.S. News & World Report ranked Hoag Hospital among the top 50 hospitals in the nation for neurology and neurosurgery in 2019-20.

Hospital for Special Surgery (New York City). Holding the No. 1 U.S. News & World Report ranking in orthopedics for 10 consecutive years, HSS surgeons perform more than 32,000 procedures annually. In 2016, the hospital reported 469 non-cervical spine fusion cases, which was well above the 48-procedure average for New York state. The hospital also focuses on research, with a 300-plus member research department that has a $45 million grant portfolio and $25 million in industry funding. Current spine-focused projects include studying spine instability, developmental deformity and tissue degeneration.

Houston Methodist Hospital. For nearly 30 years, Houston Methodist Hospital has been on the forefront of spine and neurosurgical care. The hospital is home to the center for neurodegeneration, which is comprised of 11 labs staffed with researchers working on therapies for chronic paralysis and neurologic loss. The hospital has 14 neurosurgeons on staff and was among the top 50 hospitals in the nation for neurology and neurosurgery by U.S. News & World Report for 2019-20.

Huntington Hospital (Pasadena, Calif.). Spine surgeons at Huntington Hospital specialize in treating spinal degenerative diseases such as deformities, lumbar stenosis and traumatic disorders. The hospital is home to a 32-bed orthopedic and neurological nursing unit, a 24-bed rehabilitation unit, an outpatient neurophysiology lab as well as angiography suites. In 2019-20, U.S. News & World Report ranked Huntington Hospital among the top 50 hospitals in the nation for neurology and neurosurgery.

Inova Fairfax Hospital (Falls Church, Va.). Inova Fairfax hospital is home to the largest neurological practice in the Washington, D.C., area. Nine Inova neurosurgeons perform more than 3,000 cases a year. The Inova team was the first in Northern Virginia to conduct MRI-guided surgeries to treat Parkinson's disease and a brain tumor. The Inova Neuroscience and Spine Institute has 12 specialized treatment programs and was awarded The Joint Commission's Gold Seal of Approval for its cervical and lumbar spine surgery program.

IU Health (Indianapolis). IU Health's Neuroscience Center offers patients treatment across a variety of neurological specialties, including oncology, spine surgery, stereotactic and functional neurosurgery, trauma treatment and pediatric neurosurgery. IU Health's team of neurosurgeons are at the forefront of using new technology for improving outcomes. Researchers at IU Health are currently pioneering four clinical trials on epilepsy and hematoma evacuation.

Jefferson Health (Philadelphia). Jefferson Hospital for Neuroscience is the only hospital in the Philadelphia region dedicated to neuroscience, and is one of the busiest academic neurosurgical programs in the U.S. The neuroscience program has five surgeons on staff, and in 2015, was the first in the region to offer deep brain stimulation. In 2019-20, U.S. News & World Report ranked Jefferson Health-Thomas Jefferson University Hospital among the top 50 hospitals in the nation for neurology and neurosurgery. The health system also has a robust spine program, with its spine surgeons completing around 7,000 procedures each year at inpatient and ambulatory locations. It was also the first in the country to enroll a patient in the INSPIRE 2.0 clinical trial examining treatment for spinal cord injury.

Johns Hopkins Medicine (Baltimore). Physicians in the department of neurology and neurosurgery at Johns Hopkins Medicine have been treating patients since 1889, and now perform more than 4,000 operations and 30,000 outpatient consultations each year. The Johns Hopkins Carnegie Center for Surgical Innovation, a collaboration between the departments of neurosurgery and biomedical engineering, is working on new technology to make spine surgery safer through image-guided interventions. Johns Hopkins neurosurgeons are actively researching and conducting clinical trials on Parkinson's disease, dementia and brain cancer. The Johns Hopkins Hospital was ranked No. 1 in the in the nation for neurology and neurosurgery in 2019-20 by U.S. News & World Report.

Kaiser Permanente Los Angeles Medical Center. Kaiser Permanente's neurologists and neurosurgeons perform hundreds of complex procedures each year in one of the nation's busiest neurosurgical centers. The health system's 70-year history gives it a leg up in educating the next generation of specialists through neurology and neurosurgery residency programs, as well as a neuroanesthesia fellowship program. Kaiser's Los Angeles Medical Center houses the health system's comprehensive spine surgery department as well as a radiosurgery program dating back to 1989.

Keck Medicine of USC (Los Angeles). The USC Spine Center aims to deliver a coordinated, conservative approach to spine care at four locations in the greater Los Angeles area. Specialists at USC Spine Center are all fellowship-trained faculty members at the Keck School of Medicine of USC and have collectively gained an overall patient satisfaction rating of over 4.5 out of 5 stars. USC Spine Center, which is part of USC Orthopaedic Surgery and USC Neurological Surgery, is recognized as a Blue Distinction Center for spine surgery by Blue Shield of California. Additionally, Keck Medicine of USC was ranked No. 16 in the nation for neurology and neurosurgery by U.S. News & World Report.

Lehigh Valley Health Network (Allentown, Pa.). Lehigh Valley Health Network's spine and neurology services are provided through its Institute for Surgical Excellence, where surgeons perform over 35,000 surgeries annually 70 percent more than other centers in the area. The system boasts the region's only spine neuronavigation system, as well as a 14-bed neuroscience intensive care unit. With surgeons currently involved in at least five clinical trials focused on neurology, Lehigh Valley Health Network offers patients unique opportunities to undergo new treatments in addition to surgery.

Lifespan (Providence, R.I.). With six experts on its surgical team, Lifespan's Comprehensive Spine Center is affiliated with the Providence-based Warren Alpert Medical School of Brown University, giving patients access to advanced technology and treatments. Operating at both Rhode Island Hospital in Providence and the newly opened Newport (R.I.) Hospital, the Comprehensive Spine Center is housed within the Norman Prince Neurosciences Institute. Lifespan's 13 neurosurgeons perform about 2,000 procedures annually, and they're researching the use of microelectrode arrays in epilepsy, light treatments for neurological disease, and deep brain stimulation for Alzheimer's patients.

Loyola University Medical Center (Maywood, Ill.). As an academic medical center with researchers involved in nearly 200 clinical trials, Loyola University Medical Center leverages unique neurosurgical techniques such as deep brain stimulation and stereotactic radiotherapy. Each year, Loyola's highly experienced surgeons perform over 1,000 cranial surgeries and collaborate on about 150 cranial-base operations at the Center for Cranial Base Surgery, which features a fully equipped speech and swallowing laboratory. With a 13-bed neuro intensive care unit, Loyola was ranked No. 28 in the nation for neurology and neurosurgery by U.S. News & World Report for 2019-20.

Massachusetts General Hospital (Boston). Massachusetts General Hospital's neurosurgery department performs more than 4,000 procedures every year and was the first to use deep brain stimulation to reduce epileptic seizures. MGH's team of 20 faculty neurosurgeons and 20 residents in training oversees 86 dedicated beds and a 22-bed ICU. Home to the nation's largest hospital-based neuroscience research program, MGH is committed to studying rare disorders of the nervous system, neurodegenerative disorders and effective ALS therapies. U.S. News & World Report ranked Mass General among the top 20 hospitals in the nation for neurology and neurosurgery in 2019-20.

Mayo Clinic (Rochester, Minn.). Mayo Clinic is one of the premier institutions for neurosurgery in the nation, with its Rochester location ranked No. 2 for neurology and neurosurgery by U.S. News & World Report in 2019-20. Neurosurgeons annually perform 7,000 procedures at its three campuses in Arizona, Florida and Minnesota. The health system is also on the forefront of neurosurgical research and currently has 31 clinical trials open for participation as well as a registry for primary spinal tumor research.

Medical University of South Carolina (Charleston). The Medical University of South Carolina's spine center team is a designated Blue Distinction Center for spine surgery, a mark of demonstrated quality outcomes. The hospital has $9 million in technology development funding through an in-house innovation program called Zucker Institute for Applied Neurosciences, a technology accelerator embedded within the health system to move new neuroscience innovations into the clinical settings quickly. The Medical University of South Carolina's spine program was one of the first in the state to offer patients endoscopic spine surgery, and it plans to expand its endoscopic and minimally invasive spine outpatient offerings.

MedStar Georgetown University Hospital (Washington, D.C.). The 609-bed MedStar Georgetown University Hospital has a multidisciplinary spine center and offers comprehensive neurosurgery services, including a pediatric neurosurgery program. It includes 12 neurosurgeons and spine specialists, of which five are trained in minimally invasive spine care. Its minimally invasive spine specialists have performed thousands of procedures, from discectomies to decompressions. In 2019-20, U.S. News & World Report named MedStar Georgetown University Hospital high performing in neurology and neurosurgery, as well as one of the best regional hospitals in the nation.

Memorial Hermann-Texas Medical Center (Houston). Memorial Hermann-Texas Medical Center includes the Memorial Hermann Orthopedic & Spine Hospital to offer patients the latest in spine care. The Memorial Hermann Orthopedic & Spine Hospital features 64 private patient rooms, eight two-room suites and 10 surgical suites. Patients coming to the medical center can also receive care at the Mischer Spine Center, where neurosurgeons perform more than 3,000 spine surgeries annually. The Mischer Spine Center is affiliated with Memorial Hermann Mischer Neuroscience Institute at the Texas Medical Center, which offers opportunities for patients to receive the benefits of cutting-edge research. There are 25 spine and nerve research clinical trials in progress or recently completed at the Mischer Neuroscience Institute.

MemorialCare (Fountain Valley, Calif.). Spine care at MemorialCare is offered by a multidisciplinary team of neurosurgeons, orthopedic surgeons and nonoperative specialists. Patients seeking care have the option of going to one of three California-based locations, in Long Beach, Laguna Hills or Fountain Valley. Two MemorialCare hospitals are ranked high performing in adult neurology and neurosurgery by U.S. News & World Report. The Spine Center at MemorialCare Long Beach Medical Center recently acquired robotic navigation technology to enhance precision in spine surgery.

Michigan Medicine (Ann Arbor). Michigan Medicine's neurosurgery department celebrated 100 years of offering adult and pediatric neurosurgical care last year. It includes 24 clinical faculty and eight research faculty members. Michigan Medicine's neurosurgery department also has a mission to educate and train the next generation of neurosurgical and spine care specialists via its residencies and fellowships. Its neurosurgeons are involved in an outreach program, Project Shunt, that offers neurosurgical care to children in Guatemala. U.S. News & World Report ranked Michigan Medicine No. 19 on its list of the 50 best hospitals for adult neurology and neurosurgery in 2019-20.

Milton S. Hershey Medical Center (Hershey, Pa.). Milton S. Hershey Medical Center offers spine and neurosurgery services via its spine center, which includes a 25-person care team. The spine center has developed a "back coach" program, which offers information and resources to those suffering from chronic back and neck pain. The hospital also has a robust neurosurgery research faculty that includes 17 members focusing on several key research areas, including using 3D models to understand tumor growth.

Montefiore Health System (New York City). Montefiore Health System aims to be at the forefront of neurosurgical research and care with eight comprehensive care centers and 12 neurosurgeons on staff. Earlier this year, Montefiore held its first pediatric neurointerventional symposium, which included experts from the U.S. and Canada. Montefiore Medical Center, the health system's flagship, was ranked among the top 50 hospitals in the nation for adult neurology and neurosurgery by U.S. News & World Report for 2019-20.

Moses H. Cone Memorial Hospital (Greensboro, N.C.). The 517-bed Moses H. Cone Memorial Hospital has received several recognitions for its spine care services, including being ranked No. 1 in the state for medical excellence in spinal surgery and spinal fusion by CareChex in 2018. Blue Cross and Blue Shield of North Carolina also designated the facility a Blue Distinction Center + for spine surgery last year. The hospital offers major interventional neuroradiology and neurosurgery treatments with a multidisciplinary team of neurologists, neuroradiologists other nonoperative specialists to ensure comprehensive care. Cone Health includes 19 orthopedic spine surgeons and neurosurgeons.

Mount Sinai Hospital (New York City). The Spine Hospital at Mount Sinai offers the full spectrum of cervical, thoracic and lumbar spine care. It includes 16 orthopedic and neurospine surgeons who provide care along with a team of nonoperative spine specialists. The hospital is also a preferred spine care site for retired NFL players. The health system has a strong foundation in research through various programs, including the Friedman Brain Institute, an interdisciplinary clinical and research hub focused on brain and spinal cord disorders. U.S. News & World Report ranked Mount Sinai Hospital among the top 20 hospitals in the nation for neurology and neurosurgery in 2019-20.

NewYork-Presbyterian/Weill Cornell Medical Center (New York City). NewYork-Presbyterian/Weill Cornell Medical Center's Weill Cornell Brain and Spine Center includes 24 neurosurgeons, neuroradiologists, neuropsychologists and neuroendocrinologists, who offer clinical services, conduct research and train students, residents and fellows. Patients receiving care at the center have access to the latest research-based medicine, including access to 16 neurosurgery-focused clinical trials. NewYork-Presbyterian was ranked No. 4 on U.S. News & World Report's 2019-20 list of the 50 best hospitals for neurology and neurosurgery.

Northwell Health (New Hyde Park, N.Y.). Northwell Health's Institute for Neurology and Neurosurgery includes a multidisciplinary team that offers a wide array of clinical services, and in collaboration with the Feinstein Institutes for Medical Research, the physicians and scientists conduct research and clinical trials that advance the field. U.S. News & World Report ranked Northwell's North Shore University Hospital among the top 50 hospitals in the nation for neurology and neurosurgery, while also distinguishing Lenox Hill Hospital in New York City as high performing in the specialty for 2019-20.

Northwestern Memorial Hospital (Chicago). Northwestern Memorial Hospital includes 38 neurological surgery and spine surgery specialists. It also offers a combined orthopedic spine and neurosurgical spine fellowship to train the next generation of spine and neurosurgeons. Earlier this year, the hospital launched the Northwestern Medicine Hispanic Brain and Spine Tumor Program in Chicago, which aims to reduce barriers to specialized care for the Hispanic and Latino population. U.S. News & World Report ranked Northwestern Memorial Hospital No. 5 on its list of the 50 best hospitals for neurology and neurosurgery in 2019-20.

Norton Healthcare (Louisville, Ky.). Norton Healthcare is home to the Norton Leatherman Spine Center, serving patients in Louisville and southern Indiana. Specialists at Norton Leatherman Spine perform more than 4,000 surgeries annually, and patients see its providers there more than 30,000 times a year. The fellowship-trained specialists at Norton Leatherman Spine have an average of 20 years of experience and focus on research as well as training the next generation of spine surgeons. The hospital has trained more than 100 spine surgeons who are practicing across the country.

NYU Langone Health (New York City). NYU Langone Health's neurosurgery department consists of more than 20 full-time clinical and research faculty members who take on other physicians' most complex surgical cases. Combined with the system's orthopedic spine surgeons, NYU Langone supports about 2,700 spine procedures per year. Its spine center is equipped with robotic technology and a 3D platform for planning and performing surgeries and provides operative and nonoperative treatment for about 18,000 adults and children annually. NYU Langone Hospitals is ranked No. 9 among U.S. News & World Report's top 50 hospitals for neurology and neurosurgery.

Ochsner Medical Center (New Orleans). Ochsner Health System's neurosurgery program stands out for various reasons, including being the only such program in Louisiana and one of only five U.S. centers to offer in-utero surgery to repair spinal bifida in babies during pregnancy. Each year, neurosurgeons across Ochsner Health System perform more than 1,500 adult and pediatric surgeries. The health system's spine and back care program is also highly rated, earning five stars from Healthgrades. Ochsner Medical Center, part of Ochsner Health System, is among the nation's top 50 hospitals for neurology and neurosurgery, according to U.S. News & World Report's 2019-20 rankings.

Ohio State University Wexner Medical Center (Columbus). Ohio State University is the home of an 87-bed, 60,000-square-foot brain and spine hospital that includes specialized units for stroke care, neurotrauma and traumatic brain injuries and spinal cord injury. The university also houses one of the nation's only centers that pursue innovative projects and research through the Traumatic Brain Injury Model Systems program, which is sponsored by the National Institute on Disability and Rehabilitation Research. Additionally, the university has the only rehabilitation program in central Ohio certified to handle traumatic brain injury. In 2019-20, U.S. News & World Report recognized Wexner Medical Center as high performing in adult neurology and neurosurgery.

Oregon Health & Science University Hospital (Portland). Oregon Health & Science University Hospital has pioneered innovation in neurological surgery, including North America's first deep brain stimulation surgery, the world's first neuronal stem cell transplants and an intraoperative MRI facility. It also has a leading neurosurgery training program and advanced fellowships in skull base and vascular, functional and pediatric neurosurgery. The hospital is ranked No. 44 among U.S. News & World Report's top 50 hospitals for neurology and neurosurgery in 2019-20.

Penn Medicine (Philadelphia). Penn Medicine neurosurgeons perform more than 5,000 operations annually at the Hospital of the University of Pennsylvania, Pennsylvania Hospital, Penn Presbyterian Medical Center, Penn Medicine Virtua Neurosciences and the Children's Hospital of Philadelphia. Penn Medicine's neurosurgery department also includes a research program led by basic scientists in brain, spine and nervous system diseases and disorders. Penn Medicine researchers are working on a prognostic blood test that would detect and measure neuronal proteins in the cerebrospinal fluid. In 2019-20, U.S. News & World Report ranked the health system's Pennsylvania Hospital No. 31 in the nation for neurology and neurosurgery.

ProMedica (Toledo, Ohio). ProMedica is a health system with more than 794 hospital beds serving 27 counties in Ohio and southeast Michigan. The system includes the ProMedica Wildwood Orthopaedic and Spine Hospital, which is designated a Blue Distinction Center for spine care by the Blue Cross Blue Shield Association and earned the 2018 Press Ganey Guardian of Excellence Award for physician engagement. The system's ProMedica Toledo Hospital also offers advanced navigation and robotics for complex brain and spine surgeries; it became the first in Ohio to offer the 3D mapping technology in 2017.

Rush University Medical Center (Chicago). Rush University Medical Center is one of the top 10 hospitals in the nation for neurology and neurosurgery, according to U.S. News & World Report. Its neurosurgery program consistently reports the most neurosurgical discharges in the Chicago area. In 2018, the health system reported 4,334 neurological surgery outpatient visits focused on the brain and 6,498 outpatient neurological visits focused on the spine. The health system also has a robust spine and back care program, with 12 physicians and surgeons increasingly moving toward minimally invasive and outpatient procedures. The health systems surgeons aim to stay at the forefront of patient treatment and participate in clinical trials investigating degenerative disc disease treatment, registry data for metastatic spine tumors and spinal stenosis treatment with new technology.

Saint Barnabas Medical Center (Livingston, N.J.). Saint Barnabas Medical Center houses the 22-physician neurological team of RWJBarnabas Health, the largest healthcare system in New Jersey. The Saint Barnabas Institute of Neurology & Neurosurgery is a level 4 epilepsy center with nine physicians focused on excellence in clinical care as well as clinical research. The hospital also has an innovative spine surgery department that has used a microdiscectomy technique developed by a member of its team to treat more than 500 patients. Saint Barnabas is recognized as high performing in neurology and neurosurgery by U.S. News & World Report.

Saint Luke's Hospital of Kansas City (Mo.). Saint Luke's Marion Bloch Neuroscience Institute has an advanced comprehensive stroke center accredited by the Joint Commission that leads the region in endovascular interventions and outcomes. It provides advanced stroke care to more than 2,000 patients annually, and the integrated spine program earned designation as a Blue Distinction Center+ for Spine Surgery by Blue Cross Blue Shield Association. Saint Luke's Spine Surgery Program has earned the Joint Commission's Gold Seal of Approval of Spine Surgery Certification. The system also has a level 4 comprehensive epilepsy center and a seven-member neurosurgeon team. For 2019-20, Saint Luke's Hospital of Kansas City was named among U.S. News & World Report's top 50 hospitals for neurology and neurosurgery.

Scripps Health (San Diego). Scripps Health offers neurosurgery and follow-up care at five San Diego County locations. At Scripps Health locations, physicians offer advanced techniques and technology, including minimally invasive brain surgery treatments and a robotics platform. Programs of Scripps Green Hospital and Scripps Memorial Hospital La Jolla ranked among U.S. News & World Report's top 50 hospitals for neurology and neurosurgery in 2019-20.

Spectrum Health (Grand Rapids, Mich.). Spectrum Health's neurosurgery department specializes in disorders affecting the central nervous system and offers services at five centers across Michigan, including a level 4 epilepsy center. Spectrum Health is also home to Helen DeVos Children's Hospital, which has the only pediatric neurosurgery program in the region. As the largest hospital group in West Michigan, Spectrum Health has been ranked among America's 50 best hospitals by Healthgrades for four consecutive years and has 1,600 physicians focused on more than 110 specialties.

St. Luke's Boise (Idaho) Medical Center. St. Luke's Boise Medical Center is part of the nonprofit St. Luke's Health System, Idaho's largest, comprising 14 hospitals. St. Luke's Boise, which includes four neurosurgery centers and three spine clinics in Idaho, has been ranked as a top 100 hospital by IBM Watson Health. After doubling the number of referrals to its spine care clinic in 2018, the hospital plans to open another location in 2020.

Stanford (Calif.) Health Care. The Stanford department of neurosurgery is composed of 61 neurosurgeons who perform 4,000 neurosurgical operations annually. It was named the No. 9 hospital in the nation for neurology and neurosurgery by U.S. News & World Report in 2019-20 and its stroke center was the first in the nation to be certified as a comprehensive stroke center by the Joint Commission. The department has 30 active labs researching topics including brain injury, deep brain stimulation, brain tumors and epilepsy.

Stony Brook (N.Y.) University Hospital. Stony Brook University Hospital's Neurosurgery Spine Center is a tertiary care academic medical center that has been named one of America's 100 Best Hospitals for stroke care by Healthgrades for five consecutive years. Stony Brook has more than 70 labs researching topics including spine and brain trauma, stroke and multiple sclerosis. The Neurosurgery Spine Center is the only practice in Suffolk County with two full-time pediatric neurosurgeons, and the adult neurology center sees more than 18,000 patients per year.

Sutter Health (Sacramento, Calif.). Eleven hospitals within the Sutter Health network a 24-hospital, nonprofit health system with more than 12,000 physicians received recognition from the American Stroke Association for providing a high level of stroke care in 2019. Eden Medical Center in Castro Valley, Calif., was named one of America's 100 Best Hospitals for stroke care by Heathgrades in 2019. Sutter Medical Center in Sacramento, Calif., also earned recognition as high-performing in neurosurgery by U.S. News & World Report in 2019.

Swedish Medical Center (Englewood, Colo.). Swedish Medical Center serves as the Rocky Mountain region's neurotrauma provider and has spine experts who perform an average of 90 spine surgeries per month. Part of HCA's HealthONE, Blue Cross Blue Shield Association designated it a Blue Distinction Center for spine surgery, and UnitedHealth Group designated it a Center of Excellence for spine surgery. It serves as the region's referral center for the most advanced stroke treatment and was the state's first Joint Commission-certified comprehensive stroke center.

Texas Children's Hospital (Houston). Texas Children's Hospital was the first hospital in the world to use real-time MRI-guided thermal imaging and laser technology to treat epilepsy. Named the No. 3 best neurosurgery center on U.S. News & World Report's 2019-20 list, the hospital performs more than 950 neurosurgical operations every year. It was also the first hospital to use a device similar to a pacemaker in the brain, which recognizes oncoming seizures and prevents them.

The Christ Hospital (Cincinnati). The Christ Hospital Joint & Spine Center is a seven-story facility with 14 operating rooms, four of which are dedicated solely to spine surgery. The Joint & Spine Center also offers physical, occupational and speech therapy services and physicians dedicated solely to joint, spine and brain care. Founded more than 125 years ago, The Christ Hospital has performed more spine procedures than any other hospital in the Cincinnati area.

Tulsa (Okla.) Spine & Specialty Hospital. Founded in 2002, Tulsa Spine & Specialty Hospital has a national reputation top-level patient care. It was named one of America's 100 best hospitals for spine surgery by Healthgrades. The physician-owned hospital was also honored with the Cigna Center of Excellence designation in 2018 for orthopedic back surgery and earned five stars from Healthgrades for spinal fusion in 2018. The hospital has 13 dedicated spine surgeons who perform minimally invasive procedures.

University of California San Diego Health. UC San Diego's neurosurgery division was founded in 1971 and features four intraoperative MRI and CT suites, destination skull base tumor programs and neurocritical care units. The division collaborates regularly with the UC San Diego School of Medicine, San Diego-based Scripps Research Institute and the Salk Institute for Biological Studies in La Jolla, Calif., and received $30 million in funding from the National Institutes of Health in 2018. It was ranked among the top 50 hospitals in the nation for neurology and neurosurgery in 2019-20 according to U.S. News & World Report.

UCI Health (Irvine, Calif.). UCI Health is the only academic health system in Orange County, Calif., and UCI Medical Center's neurosurgery department was recognized as high performing by U.S. News & World Report in 2019-20. The department of neurological surgery includes Orange County's first comprehensive stroke center, granted certification by The Joint Commission, as well as active research in neuro-oncology and spinal cord injury. The department frequently collaborates with other research organizations, such as UC Irvine's Reeve-Irvine Research Center, which is working to find new treatments for spinal cord injury.

UCLA Medical Center (Los Angeles). As UCLA Health's flagship hospital, UCLA Medical Center's neurosurgery department has ranked as one of the top neurosurgery programs in the nation for over 20 consecutive years by U.S. News & World Report. The department has its own neurosurgery app designed for patients with information about their physicians, procedures and hospital amenities. UCLA's Spine Center is also designated a Blue Distinction Center for Spine Surgery by Blue Shield of California.

UCSF Medical Center (San Francisco). The department of neurological surgery at UCSF Medical Center has 14 specialties, including pediatric neurosurgery. In 2011, the department developed the Quality Improvement and Patient Safety initiative with the goal of becoming a national leader in neurological surgery quality. The hospital is piloting an enhanced recovery after surgery pathway for cranial surgery as well as an opioid stewardship program. UCSF's Spine Center is also one of the largest spine centers in the country and sees over 10,000 patients a year. The department of neurological surgery at UCSF was recognized in 2019-20 as one of the top three neurosurgery programs in the country by U.S. News & World Report, which also ranks the UCSF Benioff Children's Hospitals among the top hospitals for pediatric neurosurgery in the nation.

UF Health (Gainesville, Fla.). The UF Health Spine Program provides comprehensive outpatient and inpatient treatment options at one location that features 17 neurosurgeons, three neurosurgery ORs, two neurosurgery hybrid interventional ORs and 48 private ICU patient rooms. The hospital provides complete spine services including the treatment of degenerative spinal diseases, spinal tumors as well as craniocervical junction anomalies and performs more than 1,000 procedures annually. For its 2019-20 rankings, U.S. News & World Report named UF Health Shands Hospital in Gainesville the No. 2 hospital in Florida, and it was ranked among the top in the nation for neurology and neurosurgery.

UK HealthCare Albert B. Chandler Hospital (Lexington, Ky.). UK Neurosurgery features nine neurosurgeons providing care for complex conditions including spinal tumors and deformities, stroke, ALS, and epilepsy. UK HealthCare Albert B. Chandler Hospital was ranked the No. 1 hospital in the state for neurology and neurosurgery by U.S. News & World Report's best hospitals survey for 2019-20. UK Neurosurgery collaborates with the UK Kentucky Neuroscience Institute on several research initiatives and is currently enrolling participants in ALS and epilepsy clinical trials.

UNC REX Hospital (Raleigh, N.C.). REX Neurosurgery & Spine Specialists features a team of 12 orthopedic spine and neurosurgeons providing comprehensive neurosurgical care including spinal fusion, minimally invasive spine surgery and reconstructive spine surgery. The department performs thousands of procedures each year and has been certified as a comprehensive stroke care center by The Joint Commission since 2011. UNC REX bolstered the department in the past year with the addition of an on-site spine physical therapist and a spine navigator to determine whether patients need imaging, surgery or physical therapy.

University Hospitals (Cleveland). The staff University Hospitals includes 11 orthopedic spine and neurosurgeons focused on providing exceptional patient care. The University Hospitals Spine Institute collaborates with the UH Neurological Institute, which features 13 centers of excellence and provides innovative neurosurgical therapies including CyberKnife, Gamma Knife and the NeuroBlate System. University Hospitals Cleveland Medical Center was ranked among the best hospitals for neurology and neurosurgery in the nation by U.S. News & World Report in 2019-20.

University of Alabama Hospital at Birmingham. UAB Hospital at Birmingham is widely recognized for its spine care and brain cancer research, and its specialists treat more than 4,000 patients annually. UAB Neurology and Neurosurgery has eight comprehensive divisions and seven centers that care for 26,000 patients per year. The neurosurgery department is also responsible for around 5,000 procedures annually for both pediatric and adult patients. It features research faculty and physician scientists who collaborate to advance research in conditions such as Parkinson's disease, spinal cord injury and neurovascular disorders.

University of California Davis Medical Center (Sacramento). Spine and neurosurgeons at UC Davis Medical Center actively participate in research and clinical trials spanning a range of areas including lumbar fusion, traumatic brain injury and thoracic spinal cord injury. UC Davis Health's neurosurgery department features 13 physicians on its clinical faculty and its brain tumor program incorporates 19 physicians from several subspecialties to provide optimum care for adult and pediatric patients with tumors of the nervous system. The UC Davis Medical Center ranked among the best hospitals for neurology and neurosurgery in U.S. News & World Report's 2019-20 list.

University of Colorado Hospital (Aurora). UCHealth Spine Center at the Anschutz Medical Campus is staffed by renowned spine and neurosurgeons who have built a comprehensive and award-winning program. The hospital is certified by The Joint Commission as a comprehensive stroke center and its epilepsy program is rated as a Level 4 center by the National Association of Epilepsy Centers and earned the 2019 Get With the Guidelines Stroke Gold Plus Elite Plus award from the American Heart Association and American Stroke Association for outstanding care. The department of neurosurgery features 23 physicians and U.S. News & World Report ranked UCHealth University of Colorado Hospital among the best in the nation for neurology and neurosurgery for 2019-20.

University of Iowa Hospitals and Clinics (Iowa City). The UI Spine Center has a robust program with 10 orthopedic spine and neurosurgeons who participate in next-generation surgical technology investigations to stay on the forefront of spine care. The hospital has earned the Blue Cross Blue Distinction Center+ designation for spine surgery and the University of Iowa Carver College of Medicine is often ranked in the top 10 in National Institutes of Health funding for faculty members, including neurosurgery. The neurosurgery department specializes in the surgical treatment of degenerative spine pathology, epilepsy, brain and spinal cord tumors and was designated a center of excellence by the Parkinson's Foundation in 2018.

University of Kansas Hospital (Kansas City). The department of neurosurgery at the University of Kansas Medical Center is equipped with virtual reality systems and a 3D printer to assist neurosurgeons in planning procedures and training physicians in the latest technology. The hospital includes 11 neurosurgeons and a 14-physician neurosurgery residency program. It also has a robust spine center, the Marc A. Asher, MD, Comprehensive Spine Center, which opened in 2008 and includes 27 exam rooms, four diagnostic rooms and a 4,000-square-foot outpatient rehabilitation gym.

University of Miami (Fla.) Hospital and Clinics. Neurosurgeons at University of Miami Hospital and Clinics see more than 14,000 patients and perform over 4,000 procedures annually. The hospital was named among the best hospitals in Florida by U.S. News & World Report in 2019-20 and scored as a high-performing facility in the departments of neurology and neurosurgery. The hospital integrates the latest innovations into its neurosurgical research programs including robotics, 3D interoperative imaging and deep brain stimulation.

UW Health (Madison, Wis.). The neurosurgery residency program was founded at the University of Wisconsin's department of surgery in 1942 and has been in operation ever since. UW Health features 14 neurosurgeons, 12 research faculty and two fellows. Neurosurgeons in the department see more than 1,200 brain tumor patients per year in collaboration with the UW Carbone Cancer Center. The department focuses on both clinical and investigative aspects of care for neurological diseases and is currently participating in a range of clinical trials involving brain tumors, stroke, spinal cord injury and cervical spondylotic myelopathy.

University of Utah Hospitals and Clinics (Salt Lake City). University of Utah Hospitals and Clinics provides the full spectrum of neurosurgical care to patients with cranial and spinal diseases and disorders. The faculty includes 25 physicians who provide a range of services including cerebrovascular, spinal, functional, traumatic, tumor, and pediatric neurosurgery. Physicians at the hospital are actively involved in clinical trials with current projects including pediatric neurosurgery and venous thromboembolism.

University of Virginia Medical Center (Charlottesville). Spine specialists at the University of Virginia Medical Center, in partnership with colleagues from the neurosurgery department, perform more than 1,500 spine procedures each year. The medical center's neurosurgery department is led by Jeffrey Elias, MD, who was honored as the 2018 Edlich-Henderson Innovator of the Year by the UVA Licensing & Ventures Group. At the university, Dr. Elias pioneered the use of focused ultrasound to treat essential tremor and led a clinical trial that resulted in FDA approval of the treatment.

UW Medicine (Seattle). The department of neurological surgery at UW Medicine is the primary referral center for patients in Washington, Wyoming, Alaska, Montana and Idaho who have complex neurological conditions. Twenty neurosurgeons, 15 neuroscientists and 79 adjunct clinical research faculty staff the department, and an additional 20 physicians are in its neurological surgery residency program. The neurological surgery department's outreach initiatives include National Institutes of Health-sponsored brain injury research in five Latin American countries.

UW Health (Madison, Wis.). In 1993, spine specialists at UW Health developed a minimally invasive treatment for spinal fusion surgery, becoming one of the first institutions to perform the procedure in the world and solidifying the health system as a leader in minimally invasive spine surgery. In addition to spine, providers at UW Health care for more than 1,200 brain tumor patients each year, working with the UW Carbone Cancer Center when additional treatment is needed. For 2019-20, U.S. News & World Report listed UW Health among the top 50 hospitals in the nation for neurology and neurosurgery.

UPMC (Pittsburgh). Part of the UPMC Neurological Institute, the UPMC department of neurosurgery is one of the largest academic neurosurgical providers in the nation, with more than 11,000 procedures performed annually. Among its accolades, the department ranks as one of the highest in the country in National Institutes of Health funding, and the department's chair, Robert Friedlander, MD, was elected to the National Academy of Medicine in 2018. U.S. News & World Report ranked UPMC's Presbyterian Shadyside hospital in Pittsburgh among the nation's top 50 hospitals for neurology and neurosurgery for 2019-20.

UR Medicine (Rochester, N.Y.). Patients across New York's Finger Lakes, Southern Tier and Western New York regions are served by UR Medicine Neurosurgery. At UR Medicine's Spine Center, physicians see more than 19,000 patients annually. In 2019, researchers led by the director of the hospital's department of neurosurgery's Translation Pair Research Program were selected to help the National Institutes of Health create a nonaddictive treatment for pain through clinical trials.

UT Southwestern Medical Center (Dallas). The Peter O'Donnell Jr. Brain Institute, part of the department of neurological surgery at UT Southwestern Medical Center, ranks No. 15 in the nation for neurology and neurosurgery, according to U.S. News & World Report's 2019-20 list. The department's neuro-oncology program is supported by the Annette G. Strauss Center for Neuro-Oncology and collaborates with the Harold C. Simmons Comprehensive Cancer Center. In 2018, the Decherd Foundation awarded the hospital an endowment to create an annual award to recognize exceptional care for neurotrauma patients at UT Southwestern's teaching hospital, Dallas-based Parkland Memorial Hospital.

Vanderbilt University Medical Center (Nashville, Tenn.). In addition to 21 residents, the neurological surgery department at Vanderbilt University Medical Center has 16 physician faculty members who are part of its 32-member advance practice and research team. The department sees more than 5,000 surgeries and procedures each year. In 2019, neurological surgery researchers at Vanderbilt, supported by the National Institutes of Health, for the first time found improvements in brain networks after surgery in 15 people with temporal lobe epilepsy.

VCU Medical Center (Richmond, Va.). With a 13-physician faculty, the Virginia Commonwealth University department of neurosurgery at VCU Medical Center is home to a new concept of outpatient medicine for orthopedic and neurological conditions. The VCU Health Neuroscience, Orthopaedic and Wellness Center, dubbed the "N.O.W. Center," aims to offer patient-centered care, using new software to help providers manage patients' progress during visits. The neurosurgery department at VCU Medical Center has been recognized by U.S. News & World Report, which named the hospital among the top 50 in the country for neurology and neurosurgery for 2018-19.

Vidant Medical Center (Greenville, N.C.). Vidant Medical Center is home to the only neuroscience intensive care unit in eastern North Carolina, as well as a specialized neuroscience rehabilitation unit. The hospital's neurosurgery department has 19 physicians and healthcare professionals. In April 2019, one of Vidant's neurosurgery department members co-authored a 12-month study of the use of a new neuro-spinal scaffold to treat acute thoracic complete spinal cord injury.

Wake Forest Baptist Health (Winston-Salem, N.C.). Every year, physicians at Wake Forest Baptist Health's spine center perform more than 1,000 surgeries on patients in need of treatment for back and neck disorders. Wake Forest Baptist Health is home to one of the nation's leading Gamma Knife Centers and is one of the few centers in the country to use deep brain stimulation to treat movement disorders, brain tumors, depression and Tourette syndrome. Additionally, the hospital's neurosurgery department has two neurosurgeons who specialize in pediatric care.

Follow this link:
100 hospitals and health systems with great neurosurgery and spine programs | 2019 - Becker's Hospital Review

CWRU research team receives $1 million to advance therapies for Huntington’s disease – Crain’s Cleveland Business

With the support of a $1 million grant from the Dr. Ralph and Marian Falk Medical Research Trust, researchers at the Case Western Reserve University School of Medicine are furthering their work on developing drugs to treat Huntington's disease (HD) and other neurological disorders, according to a news release.

A research team led by Xin Qi (associate professor of physiology and biophysics at the school of medicine) has been working for four years to develop drug treatments for HD, an inherited, chronic neurological disorder that causes brain cells to die, according to the release. The disorder, which has no known therapy to prevent or slow the disease, typically surfaces at age 40 and progresses until it is fatal about 10 to 20 years after diagnosis.

Based in Providence, Rhode Island, the Dr. Ralph and Marian Falk Medical Research Trust supports biomedical research with two programs: the Catalyst Research Award Program that provides seed funding to develop promising concepts, and the two-year Transformational Research Award to help researchers advance such concepts toward commercial development.

The new round of funding is a two-year grant from the trust's Transformational Award Program. With the grant, Qi and her team will "improve on novel compounds they've recently identified by screening for similar but safer and more effective potential medicines," according to the release. Her team includes Drew Adams, an assistant professor of genetics and genome sciences and co-principal investigator, and consultant William Harte, the chief translational research officer at the university.

"We will synthesize and evaluate a series of analogs of the chemical leads and assess their effectiveness in treating HD in animal models and patient cells," Qi said. "That will allow us to identify and focus on further drug development toward novel therapeutics for HD and a wider range of neurological disorders."

Read more here:
CWRU research team receives $1 million to advance therapies for Huntington's disease - Crain's Cleveland Business

Gene Therapy Industry Insights and Outlook to 2028 – Genetic Disorders, Cancer, Neurological Disorders, Cardiovascular Disorders, and Viral Infections…

DUBLIN, Jan. 28, 2020 /PRNewswire/ -- The "Gene Therapy - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The markets for gene therapy have been difficult to estimate as there only a few approved gene therapy products. Gene therapy markets are estimated for the years 2018-2028.

The estimates are based on the epidemiology of diseases to be treated with gene therapy, the portion of those who will be eligible for these treatments, competing technologies and the technical developments anticipated in the next decades. In spite of some setbacks, the future for gene therapy is bright. The markets for DNA vaccines are calculated separately as only genetically modified vaccines and those using viral vectors are included in the gene therapy markets

Profiles of 193 companies involved in developing gene therapy are presented along with 266 collaborations. There were only 44 companies involved in this area in 1995. In spite of some failures and mergers, the number of companies has increased more than 4-fold in 2 decades. These companies have been followed up since they were the topic of a book on gene therapy companies by the author of this report. John Wiley & Sons published the book in 2000 and from 2001 to 2003, updated versions of these companies (approximately 160 at mid-2003) were available on Wiley's web site. Since that free service was discontinued and the rights reverted to the author, this report remains the only authorized continuously updated version on gene therapy companies.

Gene therapy can be broadly defined as the transfer of defined genetic material to specific target cells of a patient for the ultimate purpose of preventing or altering a particular disease state.

Genes and DNA are now being introduced without the use of vectors and various techniques are being used to modify the function of genes in vivo without gene transfer. If one adds to this the cell therapy particularly with use of genetically modified cells, the scope of gene therapy becomes much broader.

Gene therapy can now combined with antisense techniques such as RNA interference (RNAi), further increasing the therapeutic applications. This report takes broad overview of gene therapy and is the most up-to-date presentation from the author on this topic built-up from a series of gene therapy report written by him during the past decade including a textbook of gene therapy and a book on gene therapy companies. This report describes the setbacks of gene therapy and renewed interest in the topic

Gene therapy technologies are described in detail including viral vectors, nonviral vectors and cell therapy with genetically modified vectors. Gene therapy is an excellent method of drug delivery and various routes of administration as well as targeted gene therapy are described. There is an introduction to technologies for gene suppression as well as molecular diagnostics to detect and monitor gene expression. Gene editing technologies such as CRISPR-Cas9 and CAR-T cell therapies are also included.

Clinical applications of gene therapy are extensive and cover most systems and their disorders. Full chapters are devoted to genetic syndromes, cancer, cardiovascular diseases, neurological disorders and viral infections with emphasis on AIDS. Applications of gene therapy in veterinary medicine, particularly for treating cats and dogs, are included.

Research and development is in progress in both the academic and the industrial sectors. The National Institutes of Health (NIH) of the US is playing an important part. As of 2016, over 2050 clinical trials were completed, were ongoing or had been approved worldwide. A breakdown of these trials is shown according to the geographical areas and applications.

Since the death of Jesse Gelsinger in the US following a gene therapy treatment, the FDA has further tightened the regulatory control on gene therapy. A further setback was the reports of leukemia following the use of retroviral vectors in successful gene therapy for adenosine deaminase deficiency. Several clinical trials were put on hold and many have resumed now. Three gene medicines have been approved by the FDA. The report also discusses the adverse effects of various vectors, safety regulations and ethical aspects of gene therapy including gene editing and germline gene therapy.

Story continues

Originally posted here:
Gene Therapy Industry Insights and Outlook to 2028 - Genetic Disorders, Cancer, Neurological Disorders, Cardiovascular Disorders, and Viral Infections...

An 8.42% Dip in Hospitalizations and 7.83% Gain in Hospitalization via ER for Orthopedics at Yale New Haven Hospital, New Haven County – Dexur

An 8.42% Dip in Hospitalizations and 7.83% Gain in Hospitalization via ER for Orthopedics at Yale New Haven Hospital, New Haven County

By: Avinash Kumar  Feb. 10, 2020

Dexur utilized Medicare claims data from 2014-Q2 to 2019-Q2 to analyze the market share of Yale New Haven Hospital of New Haven County on different metrics like Specialties, Conditions, DRG groups, Outpatient ER Visits, Hospitalizations via ER.

Yale New Haven Hospital of New Haven County maintained a consistent hospitalization rate at around 45% to 50% with 47.82% market share in 2014-Q2 and 48.65% in 2018-Q2, however when analyzed at the specialty level, there was a difference.

Orthopedics specialty of Yale New Haven Hospital, New Haven County, had seen a dip of 8.42% in hospitalizations from 2014 to 2018 with a market share of 46.61% in 2014 to 38.19% in 2018. However, based on the data analysis of 2018-Q2 to 2019-Q2, a decrease of 2.74% in the Orthopedic market share is observed. Other specialties that saw a decrease in market share are Neurology, Cardiovascular, Gastroenterology & Endocrinology, with a growth of 8.46%, 4.22%, and 4.16%, respectively, from 2014 to 2018.

Furthermore, Dexur also analyzed the share of hospitalizations admitted via ER. An increase of 6.86% in hospitalization rate via ED with 43.3% market share in 2014-Q2 and 50.16% in 2019-Q2 in New Haven County for Yale New Haven Hospital was recorded.

The Orthopedic specialty, which showed a decrease of 8.42% market share in hospitalizations, showed an increase of 7.83% in hospitalizations via ER.The market share of other specialties like Psychiatry & Mental Disorders, Neurology, and Cardiovascular increased by 8.58%, 8.12%, and 7.8% respectively from 2014 to 2018.

Continue reading here:
An 8.42% Dip in Hospitalizations and 7.83% Gain in Hospitalization via ER for Orthopedics at Yale New Haven Hospital, New Haven County - Dexur

Analysts weigh in on what to expect in biopharma this year – MedCity News

Oncology, neurology, and fatty liver disease are among the areas where one can expect to see significant activity this year, according to forecasts from investment bank analysts.

Anticipated highlights for 2020 include potentially the first regulatory approval of a drug to treat the liver disease nonalcoholic steatohepatitis, or NASH; the launches of two new drugs for sickle cell disease; and late-stage data for a drug to treat amyotrophic lateral sclerosis, among others. Several company executives also shared their insights in a story published over the weekend.

In Canaccord Genuitys forecast, analyst Edward Nash highlighted the big expectations in the disease NASH, which is the most severe form of nonalcoholic fatty liver disease. New York-based Intercept Pharmaceuticals obeticholic acid will go before an FDA advisory committee in on April 22, 2020, on the back of successful Phase II and Phase III data, thus potentially becoming the first drug approved for the disease in the middle of the year. Galectin Therapeutics, Galmed Pharmaceuticals, Genfit and Madrigal Pharmaceuticals are also expected to have Phase III data.

Allogeneic off-the-shelf cell therapies are also expected to be in the news, according to Canaccord Genuity analyst John Newman. Allogene is expected to have Phase I data in its product candidates in non-Hodgkins lymphoma and multiple myeloma in the first half of this year and by the years end, respectively. Meanwhile, Precision BioSciences is expected to have data in lymphoma and acute lymphoblastic leukemia in the first quarter. Allogeneic CAR-Ts are made with donor T-cells rather than the patients own T cells, as is the case with autologous CAR-Ts like the FDA-approved ones made by Novartis and Gilead Sciences.

In benign hematology, Newman highlighted the expected launches of recently approved sickle cell disease therapies, namely Novartis Adakveo (crizanlizumab) and Global Blood Therapeutics Oxbryta (voxelotor).

Another Canaccord Genuity analyst, Arlinda Lee, highlighted bispecific antibodies that may produce data this year, including those from Xencor, Y-mAbs Therapeutics and Zymeworks. However, BTIG analyst Thomas Shrader and colleagues pointed to both cell therapies and complex antibodies which would include bispecifics as areas of intense competition, with the large number of product candidates going after diseases like diffuse large B-cell lymphoma and acute lymphoblastic leukemia looking a little overwhelming.

Neurology and Cambridge, Massachusetts-based Biogen, the biggest company in that space also figured prominently in the forecasts. Its plan is to file for Food and Drug Administration approval of its controversial back-from-the-dead Alzheimers disease therapy, aducanumab, based on reevaluated data from the Phase III trials of the drug indicating that the amyloid beta-targeting therapy might have some efficacy after all. Declaring The 800lb gorilla returns, BTIG gave the drug about a 50% chance of winning approval when the FDA takes a closer look at the data. Anticipated topline data from the Phase III trial of BIIB067 in ALS, expected in the middle of this year, also garnered close attention.

Canaccord Genuitys report highlighted several other upcoming neurology catalysts ranging from FDA submissions to Phase III data readouts are expected for small- and mid-cap neurology-focused companies, like Acadia Pharmaceuticals, BioXcel Therapeutics, Intra-Cellular Therapies and others.

Aside from events in specific disease states and therapeutic areas, BTIGs Shrader wrote that 2020 looks like a ripe year for mergers and acquisitions, with the high-profile deals of 2019 being a good sign for the biopharma sector. Stoke Therapeutics, Alector, Gritstone Oncology and Sutro Biopharma were named as potential acquisition targets.

Photo: AndreyPopov, Getty Images

View original post here:
Analysts weigh in on what to expect in biopharma this year - MedCity News

Black and Asian Patients Face Elevated Risk of Recurrent… : Neurology Today – LWW Journals

Article In Brief

A large US-based study of recurrence of intracerebral hemorrhage (ICH) found that black and Asian patients are at a higher risk of ICH recurrence than whites, and private insurance was associated with significant reduced risk.

Black and Asian patients have a higher risk of recurrent intracerebral hemorrhage (ICH) than do white patients, according to a new longitudinal analysis published online December 12, 2019, in Neurology.

The study was led by a multi-institutional team of researchers from the US and the UK, the largest such study of ICH recurrence in a diverse US-based population.

The study also found that patients with private insurance have a significantly reduced risk of recurrent hemorrhagic stroke compared with patients on Medicaid and Medicare.

The issue of recurrence in ICH is a relatively new thing within the last decade, sayd lead study author Kevin N. Sheth, MD, FAAN, professor of neurology and neurosurgery, associate chair for clinical research in the department of neurology, and division chief for neurocritical care and emergency neurology at Yale School of Medicine.

Hemorrhagic stroke has been the deadliest stroke subtype, but over the years that mortality has declined. Now there are more survivors, and these issues surrounding what happens when you survive becomes more important. One of those issues is, what do we know about the chances of having another one?

Multiple studies have investigated racial and ethnic disparities in ischemic stroke, as well as in first-ever ICH, which is the most devastating form of stroke, associated with severe disability in most survivors and a 40 percent case-fatality rate at one month. But only one previous study had assessed these disparities in recurrent ICH. It too found that black patients were at higher risk than whites, although it did not find the same increased risk in Asians and did identify an increased risk in Hispanics.

On a large scale, our findings affirm these previous results suggesting that minority populations really are at higher risk for recurrent ICH compared to white populations, Dr. Sheth said.

In the new analysis, Dr. Sheth and his colleagues used 2005-2011 administrative claims data from the Healthcare Cost and Utilization Project California State Inpatient Database, which allows the tracking of individuals' hospitalizations over time in a large, racially and ethnically diverse population. All adult patients with a first-time diagnosis of ICH who survived to discharge and were California residents (to reduce bias related to lack of follow-up data) were included, unless they presented with a concurrent trauma diagnosis.

In the study populationcomprising 31,355 patients with an ICH diagnosis who survived to discharge1.4 percent, or 1,330 patients, experienced a recurrent ICH over a median follow-up of 2.9 years.

Compared with those who did not experience recurrence, patients with recurrent ICH were more likely to be black (11 percent vs 9 percent) or Asian (17 percent vs 14 percent, p=0.004). They were also less likely to have private insurance (18 percent vs 23 percent, p=0.001). Even after a sensitivity analysis excluding admissions with a concurrent diagnosis of infection within 30 days, black patients (HR 1.26; 95% CI 1.04-1.53; p=0.017) and Asians (HR 1.28; 95% CI 1.09-1.51; p=0.003) remained at an increased risk compared to whites, and those with private insurance remained at a reduced risk compared to patients with Medicare (HR 0.74; 95% CI 0.63- 0.86; p<0.001).

The mechanisms underlying these racial/ethnic differences remain unclear but are likely mediated by socioeconomic factors that disproportionately impact minorities, the study authors wrote.

Socioeconomic status may influence access to healthcare, early detection of hypertension and compliance with antihypertensive medications, which in turn impact the risk of recurrent ICH. Prior studies have shown that racial and ethnic minorities are less likely to achieve recommended blood pressure goals. Further study of interventions to control blood pressure in ICH survivors at both the individual and population level is warranted.

The insurance-related findings are consistent with several previous studies that have reported worse health outcomes in stroke patients with Medicaid and Medicare compared to those with private insurance. But the authors noted that it's difficult to tease out the underlying contributing factors. ...[I]t remains unknown whether these disparities represent true differences in the quality of care between insurance providers or if they represent confounding by baseline socioeconomic and health differences between groups, they wrote.

We have known for some time that there are various racial and ethnic disparities, as well as regional variation worldwide, in the incidence of ICH, said Sebastian Koch, MD, professor of clinical neurology and chief of the stroke program at the University of Miami's Miller School of Medicine. The highest rates of ICH are actually seen in Japan and China, which strongly suggests, perhaps, that there is some underlying biological reason why certain stroke subtypes may occur more frequently in some populations than others. What's particularly interesting about this study is that I think this is the first time that ICH in an Asian-American population was compared to other US racial and ethnic groups.

This paper confirms a lot of other data that we have regarding stroke in minority populations, agreed Mitchell S. Elkind, MD, MS, FAAN, professor of neurology and epidemiology at Columbia University Vagelos College of Physicians and Surgeons in New York City and an attending neurologist on the Stroke Service at the NewYork-Presbyterian Hospital.

What's unique about it is that it addresses hemorrhage and recurrent stroke, both of which are less common, so we have less data about those [conditions]. It also perhaps indirectly addresses the mechanism by which those disparities occur, because it suggests that patients with private insurance have a lower rate of recurrence than those with public insurance.

But experts were cautious about placing too much emphasis on the results regarding insurance status. There are significant confounding factors on this question, said Matthew L. Flaherty, MD, a neurologist at the University of Cincinnati Neuroscience Institute, a member of the UC Stroke Team, and a professor of neurology at the UC College of Medicine.

Patients who had recurrent ICH were less sick than patients who did not, suggesting that some of the sicker group died after discharge and were thus not at risk of recurrent hemorrhage. The recurrence group had shorter hospital stays, were less likely to be intubated, less likely to have a DNR order, and more likely to be discharged home. That suggests to me that this is a different population, probably influenced by medical comorbidities, and goals of care for these patients that might well differ in patients with different types of insurance status. This study could not identify patients who died outside the hospital. It's also likely there are unidentified socio-economic factors that differ by insurance status. Administrative databases in general are subject to things like coding errors, which is a limitation.

Nonetheless, said Dr. Elkind, it is reasonable to suggest that neurologists should be aware of a potentially heightened risk of ICH recurrence in minority populations and those who may have less access to health care resources. The underlying problem is often access to health care, whether it is doctor's visits or medications, so one may want to be especially attentive to those patients who may not have such access.

This paper adds evidence that despite our best attempts to adjust for common risk factorsthings like age, blood pressure, smoking, diabetes, and so onthere is a component to stroke recurrence, including ICH, that may be based on the genetics behind race or ethnicity, said Lee Birnbaum, MD, interim director of stroke at UT Health San Antonio.

We can't change a person's genetics, but we can certainly focus on known risk factors for first-time and recurrent ICH, and the most significant risk factor across all races and ethnicities is hypertension. Blood pressure is not just a primary care issue: neurologists should always be involved in the treatment of hypertension for stroke prevention, particularly after an ICH.

He noted that some blood pressure medications can be more or less effective in different populations, so the selection of these medications can be race- or ethnicity-specific. We also know that the Asian population can have more intracranial atherosclerosis than other populations, and so that may be a group to target more aggressively with cholesterol-lowering medicines, he said. However, there is evidence that intense lowering of LDL and cholesterol may possibly increase the risk for recurrent ICH, so the verdict on just how aggressive to be about lowering cholesterol after an ICH is still out.

At the clinician and practice level, treatment and management must take into consideration each patient's social situation, said Salvador Cruz-Flores, MD, FAAN, a stroke neurologist who is professor and founding chair of the department of neurology at Texas Tech University Health Sciences Center at El Paso.

Consider the difficulties that this person may have to even get to your office and try to find ways to adapt and allow them access to care. We aren't in a position to give away medications, but sometimes we tend to use the expensive ones as opposed to cheaper ones that may have similar efficacy in controlling blood pressure. We need to have culturally appropriate plans to engage and educate different populations in the importance of adherence to treatment.

Two secondary prevention trials for ICH survivors will be launching in 2020. ASPIRE is a randomized, double-blinded, phase 3 clinical trial designed to test the efficacy and safety of anticoagulation, compared with aspirin, in patients with a recent ICH. SATURN, a multicenter prospective, randomized, open-label, and blinded end-point assessment (PROBE) trial, aims to determine whether continuation vs. discontinuation of statin drugs after spontaneous lobar ICH is the best strategy.

This is very exciting; there has never before been a secondary prevention trial in ICH in the United States, said Dr. Sheth. Now there are more survivors, and the nihilism in the field is being chipped away.

Given this environment, Dr. Cruz-Flores suggests that the AAN and other professional societies should push to identify societal-level interventions to help narrow the disparities in access and outcomes identified by the new paper and the larger body of evidence around stroke care. That's where we can do better and where we are probably failing, he says. For example, the AAN could develop evidence-based guidelines to manage stroke recurrence in underserved populations. There must be a way that we as a society can manage these recurring and disproportionate risks for stroke.

Dr. Sheth agrees. As we do for other diseases, and for cardiovascular health broadly, we must better understand the details about disparities and access to care in ICH. What are the real drivers and how do we attack them?

Dr. Sheth, the senior author, receives research grants from the NIH and the American Heart Association. Drs. Koch, Elkind, and Salvador-Cruz had no competing interests.

More here:
Black and Asian Patients Face Elevated Risk of Recurrent... : Neurology Today - LWW Journals

Heres why not all plant-based diets are good for you – Hindustan Times

While a lot more people are shifting to plant-based diets so as to achieve positive health results, they might not be reaping the benefits to the fullest as it is found that not all plants can do good to you.

In a new study, researchers have found that all plants arent good especially for the undernourished or people who depend on a single plant diet.

They also cautioned that growing interest in wild edibles raises the risk for people in wealthy countries, too, especially as some plants may become more toxic with changing climate, according to the findings published in the journal Environmental Neurology.

The bottom line is that plants and fungi were not put here for our benefit - they need to defend themselves, said Peter Spencer, professor of neurology in the OHSU School of Medicine and an affiliated faculty member of the Oregon Institute of Occupational Health Sciences at OHSU.

In the study, researchers catalogued a quartet of plants that sicken or kill undernourished people around the globe. The adverse neurological effects of food dependency on plant components with toxic potential constitute a significant global health issue, explained researchers.

Those in the list of the researchers include the potential neurotoxic effects of fruit of the ackee tree, an evergreen native to West Africa and favorite of Jamaica; lychee fruit, a delicious tropical fruit from southern Asia now eaten worldwide; grasspea, a protein-rich legume eaten on the Indian continent and the Horn of Africa; and cassava, a plant whose roots and leaves are consumed in across sub-Sahara.

Researchers elucidate ways in which they can rapidly and fatally affect brain function or, in the case of cassava and grasspea, gradually induce crippling disease.

This depends on the amount of plant product consumed along with the poor health of the people eating it; and the relative availability of each of these plants due to poverty, hunger and, increasingly, climate change.

Many people in Africa rely on cassava as a primary food source because it grows well in arid soils. But when stressed by drought, the concentration of its chemical defences increase at the same time water to wash out the toxic factors is in short supply. Those dependent on cassava develop an irreversible struggle to walk.

Researchers focused decades of their research in the field and laboratory on grasspea, a tasty legume that also causes tremor, muscle weakness and even paralysis in those who depend upon it for sustenance.

Unfortunately, Palmer said, people may well become increasingly exposed to potentially toxic plants as the climate warms and the global population expands, especially in low-income countries.

This is very concerning, particularly because many people are going to need to rely on these crops in the future, she said.

Spencer believes the exposome - the food we eat, the air we breathe, the chemicals we are unwittingly exposed to - is every bit as important in determining human health and preventing disease.

Prevention of brain disease is our principal goal-seeking and understanding the chemical causes of disease and minimizing human exposure, Spencer said.

(This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed. )

Follow more stories on Facebook and Twitter

Go here to read the rest:
Heres why not all plant-based diets are good for you - Hindustan Times

Dubai hosts the 24th World Congress of Neurology – Gulf News

H.E. Humaid Al Qutami, Director General of DHA, attended the event last week Image Credit: Nadeem Rasheed, DHA

In a bid to provide international experts and specialists in the field of neurology with a platform to exchange experiences and knowledge, the World Congress of Neurology 2019 (WCN2019) took place in Dubai last week.

The event, in its 24th edition, was held under the patronage of His Highness Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai and Chairman of the Dubai Executive Council and was inaugurated by His Highness Sheikh Ahmed bin Mohammed bin Rashid Al Maktoum, Chairman of the Mohammed bin Rashid Al Maktoum Knowledge Foundation.

The congress, which was organised by the World Neurology Association and took place from October 27 to 31, discussed worldwide advancement of neurology in both scientific and clinical aspects, under the slogan Accelerating the Pace of Change.

The conference aimed to disseminate research, promote collaborative work in various fields of neurology and develop ethical guidelines for professional practices, especially in the areas of Alzheimers disease, strokes, multiple sclerosis, peripheral nerve diseases and Parkinsons disease.

The event also featured active discussions and cutting edge lectures by the worlds top scientists and neurologists in all fields of neurology including clinical medicine, research and future plans in neurology.

The congress hosted 165 speakers and 265 lectures. It also included an accompanying exhibition featuring 45 exhibitors.

A total of 4,000 participants from 125 countries took part in the event, which is considered the biggest congress on neurology in the world.

Dubai won the bid to host the congress, which takes place every two years, after competing with Johannesburg in South Africa.

In his keynote speech, His Excellency Humaid Al Qutami, Director General of DHA, commented on hosting this prominent event, saying:

Without a doubt, organising this medical event in the UAE and in Dubai the home of international government summits and forums will mark a new shift in the field of neurology, one of the most important medical specialties.

First, we would like to point out that our country and government believes that the wellbeing and health of our people is of its highest priority.

Excerpt from:
Dubai hosts the 24th World Congress of Neurology - Gulf News

Valeritas Presents Positive h-Patch Apomorphine Study Data at the World Congress of Neurology (WCN 2019) – GlobeNewswire

BRIDGEWATER, N.J., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go Wearable Insulin Delivery device, which uses its proprietary h-Patch technology, announced positive data from its preclinical pharmacokinetic (PK) study of apomorphine (Apo) subcutaneous infusion was presented today at the 24th World Congress of Neurology held in Dubai, UAE.

In the poster presentation titled Delivery of Apomorphine via Subcutaneous Infusion with the h-Patch Wearable Device, the data demonstrated that 400ul of a 25mg/ml Apo solution delivered with the h-Patch technology was rapidly absorbed and was detected in plasma within two hours of the start of infusion. Additionally, Apo was still detectable in plasma 24 hours after completion of h-Patch infusion, or 48 hours in total.

Given both the side effects of oral dosing of Levodopa as well as the lack of small form factor subcutaneous delivery devices to effectively deliver Apo, we believe there is a significant unmet need that our wearable h-Patch device can satisfy for the effective delivery of Apo, said John Timberlake, President and Chief Executive Officer of Valeritas.

Valeritas proprietary h-Patch device is a simple all-in-one, fully disposable, drug delivery technology that can facilitate the simple and effective subcutaneous delivery of injectable medicines to patients across a broad range of therapeutic areas. The Companys V-Go is the first FDA-approved product that utilizes its h-Patch technology. To date, more than 20 million V-Go insulin delivery devices have been sold in the United States.

Treatment of advanced Parkinsons disease (PD) remains challenging, with fluctuations in motor status often resulting in patients becoming severely handicapped. The magnitude and pattern of the motor response to a single dose of subcutaneously administered Apo are qualitatively comparable to that of oral levodopa; however, side effects of oral dosing (dizziness, nausea, vomiting, etc.) can be problematic.

Close to a dozen clinical studies have shown subcutaneous Apo infusions are successful in aborting off periods, reducing dyskinesias, and improving PD motor scores with the added benefit of sparing the patient the challenging side effects of oral Levodopa. However, bulky infusion pumps requiring delivery of relatively large volumes of therapeutics remain a barrier to the development of therapeutic products that are patient and caregiver friendly, which may represent an opportunity for Valeritas comparatively smaller h-Patch technology.

About Valeritas Holdings, Inc.

Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas flagship product, V-Go Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for adult patients requiring insulin that is worn like a patch and can eliminate the need for taking multiple daily shots. V-Go administers a continuous preset basal rate of insulin over 24 hours, and it provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts.

More information is available atwww.valeritas.com and our Twitter feed @Valeritas_US,www.twitter.com/Valeritas_US.

Forward-Looking Statements

This press release may contain forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Valeritas technologies, business and product development plans and market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others: the ability to raise the additional funding needed to continue to pursue Valeritas business and product development plans; Valeritas' expected cash burn rate and its ability to continue to increase new and total prescription growth; the expected benefits of the debt exchange on Valeritas cash runway and its anticipated operating costs following the debt exchange (the $2 million minimum debt covenant remains in place following the debt exchange, which will continue to limit Valeritas ability to finance its operations); the effects of both the new issuance of Series B Convertible Preferred Stock and the May 2019 reverse stock split on the trading price of Valeritas common stock, in both the short and long-term; the ability to continue to commercialize the V-Go Wearable Insulin Delivery device with limited resources, competition in the industry in which Valeritas operates and overall market conditions; the inherent uncertainties associated with developing new products or technologies; the potential commercial use of the h-Patch technology for subcutaneous delivery of GLP-1, Apo or CBD is dependent on Valeritas ability to identify one or more potential collaboration partners and enter into mutually agreeable collaboration agreements (neither the delivery of GLP-1, Apo or CBD by h-Patch is currently cleared for use by the FDA); our statements that (i) subcutaneous Apo infusions appears to offer qualitatively comparable benefits to that of oral levodopa and (ii) based on initial studies, subcutaneous infusion of CBD appears to offer several distinct advantages over oral dosing of CBD, and other potential benefits of the h-Patch technology to deliver GLP-1, Apo or CBD is based on third-party clinical studies not conducted by Valeritas; however, additional studies or research may be needed by our potential partners to demonstrate to the U.S. Food and Drug Administration (FDA) that delivery of GLP-1, Apo or CBD via the h-Patch technology will offer consistent results to the initial Valeritas study; and the FDA or other regulatory agencies may require Valeritas collaboration partners to demonstrate the safety or effectiveness of subcutaneous infusion of GLP-1, Apo or CBD through the h-Patch technology before any of those products can be commercialized, which can be a lengthy, and uncertain process, and the FDA may delay or require additional information to provide clearance for use with our RHI or our V-Go SIM product. Statements or claims made by third parties regarding the efficacy or functionality of V-Go as compared to other products are statements made by such individual and should not be taken as evidence of clinical trial results supporting such statements or claims. Any forward-looking statements are made as of the date of this press release, and Valeritas assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Valeritas files with the SEC available at http://www.sec.gov.

Investor Contacts:Lynn Pieper Lewis or Greg ChodaczekGilmartin Group646-924-1769ir@valeritas.com

Media Contact:Kevin KnightKnight Marketing Communications, Ltd.206-451-4823pr@valeritas.com

Read this article:
Valeritas Presents Positive h-Patch Apomorphine Study Data at the World Congress of Neurology (WCN 2019) - GlobeNewswire

Highlights from Day Two of the World Congress of Neurology 2019 – WFN News

Report byProf. Tissa Wijeratne MD FRACP FRCP (Edin) FRCP (London) FAHA FAAN (USA)

An exciting second day in Dubai started at 7.00 am with a masterclass in Neuro-Opthalmology. It was attended by a packed audience presented with an interestingassortment of cases by Dr Gordon Plant and Dr Vivek Laal.

The Plenary lecture on Reading in the Brain: Mapping the massive impact of literacy on brain circuits" was delivered by Prof. Stanislas Dehaene.

Dr Adrian Owen delivered the second plenary lecture on The Gray Zone and Brain Death."

Professor Russel Foster delivered the Soriano award lecture on light, circadian rhythms and sleep, mechanisms to new therapeutics. The first part of this brilliant lecture considered the discovery and clinical importance of the third photoreceptor system of the eye. The second part of the talk went on to discuss the connection between photoreceptor signal light, clockwork and sleep. He went on to discuss the detailed molecular changes during the circadian rhythm.

Dr Tedros, Director-General, World Health Organisation,delivered a video message on the WHO and recent collaborative outcomes.

Professor Raad Shakir, Immediate past president, WFN delivered the important news on ICD-11 and its impact on the future of neurology.

Professor William Carroll, President WFN delivered a lecture on the global role of World Federation of Neurology. Professor Bo Norrving delivered the much-awaited news on the implications of the reclassification of stroke as a neurological disease.

The WFN- Young neurologists, trainees and medical students informal gathering was a great success. Professor Tissa Wijeratne moderated the discussion. There was active participation. WFN trustees and the high-level leadership was available for the discussion and future of this group looks promising.

The number of parallel sessions covering dementia, headache disorders, movement disorders, MS and demyelinating disorders, dementia, neurooncology, advocacy, stroke medicine were highly successful.

Read the rest here:
Highlights from Day Two of the World Congress of Neurology 2019 - WFN News

Final day highlights from the World Congress of Neurology 2019 – WFN News

Report byProf. Tissa Wijeratne MD FRACP FRCP (Edin) FRCP (London) FAHA FAAN (USA)

The atmosphere has been electric at the World Trade Centre, Dubai over the past five days. The excitement and joy of being in Dubai at the World Congress, serious as well as non-serious discussions among colleagues young and old, east and west, hustle and bustle, the diversity changed the WTC to a totally different place.

It has all come to an end today. What a fabulous world congress of neurology it has been! It is with mixed emotions I write this daily report to the membership worldwide.

The day began with an hour-long teaching course on headache disorders by Associate Professor Richard Stark, Treasurer and Trustee of the World Federation of Neurology. Given the enormous success of our world brain day campaign, it was fitting to focus on headache disorders on the final day.

There are one billion migraine patients with significant disability and a lot of room for improvement. The World Federation Neurology will continue to work with its member organisations and International Headache Society with a view to reaching out to resource-limited countries in the world as a priority.

Professor Nicolelis delivered the first plenary on Brain-Machine interfaces from basic sciences to neurorehabilitation. The research raises the possibility that properties of a robot arm, or other neutrally controlled tools, can be assimilated by brain representations as these tools were extensions of the subjects own body.

Professor Walter Koroshetz delivered the second plenary lecture on the promises of brain initiative for those with neuro/mental/substance disorders with a lot of promise for the future.

The paper discussed the current research on how brain circuits process information to enable human behaviour. The recent advances in the field opened up extraordinary possibilities for understanding animal and human behaviour and a lot of potential translating to the bedside.

The much-awaited semifinals and finals of the Tournament of the Mind was a sheer joy to watch, participate (delegates could vote on their smartphones to test their own knowledge), and enjoy the battle for the supremacy for the mind and brain!Sri Lanka, Hong Kong, Malaysia and India fought hard to secure the top spot but after a very close battle, Hong Kong pulled through as the overall winner. 4 other countries competed in a tiebreak with Sri Lanka taking 2nd place runners up. Warm congratulations to all teams, in particular to Hong Kong and Sri Lanka.

The 24th World Congress of Neurology has been an immense success. Let us meet again in Rome. We look forward to seeing you all in Rome in 2021.

Safe travel home, everyone. Keep visiting our website and social media streams to keep in touch.

See original here:
Final day highlights from the World Congress of Neurology 2019 - WFN News